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ABSTRACT 
 
Proton therapy has been substantially growing in use and acceptance for the 
treatment of cancer in the past years. However, the long-term risks of secondary 
malignancies possibly associated with proton therapy have not been studied in detail due 
to the lack of well-established methodology and available patient information. Organ-
specific radiation dosimetry in proton therapy is complicated but crucial in 
epidemiological investigations of radiotherapy patients. Scatter neutrons generated in the 
treatment head and inside the patient via nuclear interactions need to be taken into 
account in normal tissue dose assessment. The present study establishes the dosimetry 
methods for patient-specific organ dose calculations from proton therapy and methods to 
improve dose reconstruction of organ doses in out-of-field regions not typically covered 
by radiographic images.  
First, using limited radiographic data from Computed Tomography (CT) 
modalities combined with the library of body size-dependent computational human 
phantoms, methods were created to generate a full-body patient-specific phantom. This 
allows for full-body neutron dose calculations using Monte Carlo radiation transport 
methods. Second, a computer simulation model was developed to reconstruct a patient-
specific proton therapy treatment within Monte Carlo radiation transport codes using 
already available patient radiotherapy log files and reference measurements from the 
Maryland Proton Treatment Center (MPTC). The method will allow for calculation of 
normal tissue dose in patients at MPTC and will be extended to other proton therapy 
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machines installed at other proton therapy facilities. Finally, based on the normal tissue 
doses calculated for the pediatric phantoms, the risk of second neoplasms was calculated 
based on the BEIR VII risk models. Two pediatric computational phantoms were 
imported into the treatment planning system at MPTC.  
Full-body organ dose calculations were carried out using the Monte Carlo 
calculation modules developed in the current study and the radiation weighting factors 
reported by the International Commission on Radiological Protection (ICRP) followed 
by the assessment of the risks of developing second neoplasms. Lifetime attributable risk 
were low, maximum being for the lungs of 0.111% for the one-year-old case and 0.108% 
for the five-year-old case. 
In conclusion, key methods for normal tissue dosimetry in proton therapy 
patients were developed and validated. Methods established in this dissertation will be 
applied to support ongoing international epidemiologic studies of pediatric patients 
undergoing proton therapy. 
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1 INTRODUCTION 
1.1 BACKGROUND 
In the last several decades, advances in cancer treatments and early detection have 
greatly increased the likelihood of post-treatment patient survival. Overall, the number 
of cancer survivors in the United States has tripled since 1971 and has been growing by 
2% each year [1]. The likelihood that children with cancer will survive 5 years or longer 
after treatment has increased by more than 50% between 1975 and 2006 [2]. One reason 
for this increasing success has been due to advancements in radiation therapy, with 
nearly two-thirds of all cancer patients receiving radiotherapy as part of their treatment 
[3]. During treatment of patients with solid cancers, the main concern is to irradiate the 
cancerous tissue enough to damage. A treatment plan is optimized to maximize the 
tumor dose while minimizing the dose to normal tissue near the treatment site to avoid 
short-term toxicities. However, no matter how careful any treatment is planned, dose is 
also delivered to normal tissues and organs.  
Though not considered as critical during treatment, long-term effects from the 
absorbed dose due to scatter radiation deposited in areas further from the treatment 
target, or “out-of-field”, may also be of concern. As cancer survival rates improve, it 
becomes increasingly important to consider the impact this unintended radiation 
exposure to normal tissue may have on the patients’ long-term health and quality of life 
[4]. Radiotherapy has been implicated as a contributor to late-term toxicities such as 
second primary cancers [5] and radiation-induced cardiovascular disease (RICD) [6]. In 
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fact, second cancers are the most common cause of treatment-related deaths in long-term 
survivors of pediatric malignancies [7]. Therefore, minimizing dose to normal tissue due 
to incorrect dose planning and from scatter radiation is critical, especially for pediatric 
patients. Children have more radiosensitive tissues and organs and an expected longer 
life expectancy.  
Proton therapy is a relatively new cancer treatment modality that lacks 
epidemiologic studies of long-term effects. While it theoretically should improve 
outcomes and early studies seem promising, large epidemiologic studies showing long-
term improvements have yet to be conducted. Such studies, however, require accurate 
estimates of absorbed dose to the specific organs and tissues for individual study 
subjects allowing the quantification of risk and an assessment of dose-response 
relationships [8].  
It is necessary to create accurate risk models to be able to quantify and judge the 
risks versus benefits of modern radiotherapy techniques. While population-based models 
have been developed to calculate risks of cancer incidence and mortality [9] from 
radiation, there are no such models specifically dedicated for proton therapy treatments. 
The present work studies and establishes the methods to aid in dose reconstruction of 
proton therapy treatments including a method to simulate normal tissue dose from active 
scanning proton therapy. Afterwards, these dosimetric modules are used along with the 
most recent risk models from NCI and BEIR VII [10] to calculate the corresponding risk 
from proton therapy treatments for several pediatric patient cases. 
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1.2 ADVERSE EFFECTS OF RADIOTHERAPY  
Two of the most frequent adverse effects of radiotherapy are second malignant 
neoplasms (SMN) and radiation-induced cardiovascular diseases (RICD). In the United 
States, children treated between 1970 and 1986 had a 30-year cumulative incidence rate 
of second malignant neoplasms of 20.5% [11]. And for patients with Hodgkin’s 
lymphoma, testicular cancer, and certain pediatric cancers, SMNs have become a major 
cause of morbidity and death [1]. Radiotherapy-associated CVDs are a wide spectrum of 
heart disorders that may result in morbidity and mortality, most notably after Hodgkin’s 
lymphoma and breast cancer treatments [12]. As a result of these growing concerns, the 
National Council on Radiation Protection and Measurements (NCRP) convened an 
expert scientific committee in 2011 to assess associations between radiotherapy and 
SMNs and CVDs [13]. Two major recommendations the NCRP prescribed was:  
(1) prioritizing research to include long-term large-scale follow-up of extant 
cancer survivors and prospectively treated patients to characterize risks of SMNs and 
CVDs in terms of radiation dose and type and  
(2) to construct comprehensive risk prediction models for SMNs and CVDs.   
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1.3 RADIATION-INDUCED CANCER 
Risks of developing cancer are known to be related to several confounding 
factors such as age, sex, time, and ethnicity, exposure to environmental agents [14], and 
medical exposures such as radiological scans, nuclear medicine studies, and external 
beam radiotherapy [15-19]. For most carcinogens, the exposure-occurrence relationship 
is usually not a simple dichotomy of two outcomes but lies on a probability continuum. 
By definition, all carcinogens at sufficiently large doses do increase the risk of cancer, 
and it is generally accepted there is no increase in risk in the absence of any exposure (! = 0). Risks of cancer-induction following a radiation exposure is considered 
stochastic: different people receiving the same amount of radiation dose may or may not 
develop cancer, but a person receiving a higher dose will have a higher probability of 
developing cancer [20].  
 In the common presence of background radiation, and risks of developing of 
cancers due to other factors, it is difficult to obtain unequivocal evidence of increased 
risk due to low levels of radiation. Even in the favorable situation in which the baseline 
risk is relatively well-estimated compared to the risk of the exposed group, the ability to 
reliably detect small increases in risk associated with exposure requires a large number 
of exposed individuals at risk. This is because at low levels of exposure, cancer risks 
associated with exposure are small relative to baseline, or background, risks and 
comparatively, the increase in observed cancer rates associated with an exposure are 
small. This requires a large group of individuals to be followed for long periods of time 
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to provide sufficiently precise and accurate estimates of risk associated with radiation 
exposure. 
 
1.3.1 Cancer risk estimates 
In the present work, absorbed doses and risk estimates are calculated for patients 
receiving active scanning proton therapy. Absorbed doses are calculated for all organs, 
and the long-term risk from is calculated based on current risk models. The risk models 
used in this work are based on those recommended by the National Research Council’s 
Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation. 
In its most recent report, Health Risks From Exposure to Low Levels of Ionizing 
Radiation BEIR VII Phase 2 [10], models have been developed as functional 
relationships between radiation dose and induced cancer for a variety of endpoints, such 
as lifetime risks of incidence and mortality.  
These risk models use data based primarily on the Life Span Study (LSS) cohort 
of survivors of the atomic bombings in Hiroshima and Nagasaki. The study of these 
tragic events allowed epidemiologists to investigate the relationship between dose and 
risks of secondary effects amongst varying populations, people of varying sex and ages, 
being one of the first studies with such high-quality cancer incidence data [21]. In 
addition to the LSS, the BEIR VII committee reviewed and incorporated the vast 
literature on both medically exposed persons and nuclear workers exposed at relatively 
low doses, epidemiologic studies on mortality [22], and other models for estimating 
cancer risks from exposures to low level radiation such as those by the United Nations 
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Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) [23] and by the 
National Cancer Institute (NCI) [24].  
The development of risk models for site-specific cancers is limited by current 
epidemiologic data. For A-bomb survivor data on solid cancers, parameter estimates 
based on site-specific data are less precise than those based on all solid cancers analyzed 
as a single group. It is especially difficult to detect and quantify the modifying effects of 
variables such as sex, age at exposure, and attained age for site-specific cancers [10]. 
Such risk estimates are subject to several sources of uncertainty due to inherent 
limitations in epidemiologic data and in the understanding of exactly how radiation 
exposure increases the risks of cancer in the low-dose regions. In addition to statistical 
uncertainties, risk may depend on the type of cancer, the magnitude of the dose, the 
quality of the radiation, the dose-rate, the age and sex of the person exposed, exposure to 
other carcinogens such as tobacco, and other characteristics of the exposed individual. 
While a patient may receive more than simply radiotherapy during his or her treatment, 
this work focuses on radiation received during radiotherapy and therefore only cancer 
incidence risks due to the radiotherapy are estimated. Additional risks due to other 
treatment modalities are out of the scope of this work. In addition, to calculate mortality 
risks of cancer patients, it would be necessary estimate both the curative effect due to the 
treatment in combination with its secondary negative effects, which is also out of the 
scope of the current work.  
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1.3.2 Risk Models 
The basic measures used to compare disease occurrence in exposed and unexposed 
populations are risks and rates. The association between exposure and a secondary effect 
is aided by statistical models of risks of secondary effects as functions of dose, typically 
stratified by variables such as sex and age. Model-based estimation provide an efficient 
way to utilize the information in available epidemiologic data and a means of deriving 
risk estimates for dose profile combinations of specific cases [10]. 
Compared to unexposed populations, the elevated risks of exposed populations are 
manifested by an increase in cancer incidence (and mortality) rates. An incidence 
rate,	*(+) is a measure of the disease occurrence used in cancer epidemiology referring 
to new cases of disease occurring among previously unaffected populations. The cancer 
risk of populations exposed to radiation, such as that from radiotherapy, can be 
quantified by the difference between the rates of cancer incidence of the unexposed and 
cancer incidence of the exposed populations. The difference in incidence rates, or the 
Excess Absolute Risk (EAR) is described by, 
 ,-.(+) = 		 */(+) − *1(+) (1) 
where */(+) refers to cancer incidence rate of an exposed population and *1(+) is the 
cancer incidence rate of unexposed population.  
A second common measure of discrepancy between an unexposed and exposed 
populations is the Relative Risk	(..), quantified as, 
 ..(+) = 	 *(+)//	*(+)1 (2) 
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which describes the multiplicative increase in incidence rates associated with exposure 
[10] and the Excess Relative Risk (,..),  
 ,..(+) = 		..(+) − 1  (3) 
relating the exposed and unexposed rates as, 
 */(+) = *1(+){1 + ,..(+)} (4) 
Most site-specific cancers have been found to follow a linear dose-response with a 
few exceptions, such as leukemia, which has been found to be more accurately described 
by a linear-quadratic model [11, 25, 26]. In this work, however, only cancer induction 
that use linear dose-response models are considered and described.  
In this context, a stochastic linear dose-response model presupposes that the risk of 
cancer incidence increases linearly with dose. However, the slope of the line, which 
measures the increase in risk (for a unit increase in dose), has to be estimated from data 
using the method of maximum likelihood [27]. With linear dose-response functions, the 
general models for the ERR and EAR using models to calculate the instantaneous risk 
that a population receives at an age, a, is described as,  
 */(7, 8, 9, :, ;) = 	 *1(7, 8, 9, :){1 + ,..	(!, 9, <, 8)} (5) 
and, 
 */(7, 8, 9, :, ;) = 	 *1(7, 8, 9, :) + ,-.	(!, 9, <, 8) (6) 
where *1(7, 8, 9, :) is the background rate at zero dose, and depends on location	7, sex 8, 
attained age, 9, : is the birth cohort, < is the age at exposure, 9 is the attained age, and 8 
is the sex identifier.  
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To calculate the increased risk due to radiation, the ,-. and ,.. are calculated 
as a function of dose an individual receives, 
 ,-.	=>	,..	(!, 9, <, 8) = ! ∗ @A ∗ <BC ∗ 9D	 (7) 
where ! is the dose expressed in Sieverts, @A, is the ERR or the EAR/10E FG, 9 is the 
attained age, e is the age at exposure, and 8 is the sex-specific tag. The BEIR VII 
committee suggests that the ERR for solid cancers (except for breast and thyroid cancer) 
depends on age only for exposures at before 30 years of age, replacing e with, 
 <∗ 	= 	 (<	 − 	30)/10 and is 0 for e > 30. The parameter γ gives the per-decade increase 
in age at exposure for the range 0–30 years. Relevant parameters for ERR and EAR are 
shown in Table 1. 
 
Table 1. BEIR VII's preferred EAR and ERR parameters for estimating site-
specific of solid cancer incidence. 
 
Organ @I @J K L @I @J K L 
Stomach 0.21 0.48 -0.3 -1.4 4.9 4.9 -0.41 2.8 
Colon 0.63 0.43 -0.3 -1.4 3.2 1.6 -0.41 2.8 
Liver 0.32 0.32 -0.3 -1.4 2.2 1 -0.41 4.1 
Lung 0.32 1.4 -0.3 -1.4 2.3 3.4 -0.41 5.2 
Breast  0.51 0 -2  9.4 -0.51 3.5 
Prostate 0.12  -0.3 -1.4 0.11  -0.41 2.8 
Uterus  0.055 -0.3 -1.4  1.2 -0.41 2.8 
Ovary  0.38 -0.3 -1.4  0.7 -0.41 2.8 
Bladder 0.5 1.65 -0.3 -1.4 0.2 0.75 -0.41 6 
Thyroid 0.53 1.05 -0.83 0     
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1.3.3 Lifetime Attributable Risk (LAR) calculations 
In this study, the lifetime attributable risks (LAR) are also calculated from proton 
therapy treatments. The LAR is an approximation of the risk that a radiation-induced 
second cancer will occur during an exposed population’s lifetime. As such, LAR 
calculations include cancers that would develop without exposure but occur sooner in 
life because of exposure to radiation. The LAR can be estimated as an time-integral of 
excess risks for all attained ages (up to the age of 100 years) using either ERR or EAR or 
a combination of the two [10] : 
 M-.(!, <) = 	N I(!, <, 9) ∗ "(9)"(<) ;9		OPPQRCST  (8) 
where L is the latent period (5 years for solid cancers) and the ratio "(9)/"(<) is the 
probability of surviving from the exposed age, e, to age a for the unexposed population, 
with the I(!, <, 9) defined as, 
 I(!, <, 9) = 	,-.(!, <, 9) (9) 
or, 
 I(!, <, 9) = 	,..(!, <, 9)	*1U (9) (10) 
where the parameter 	*1U (9) is the age- and gender-specific baseline cancer incidence 
rates at the attained age a [10].  
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1.4 EPIDEMIOLOGIC STUDIES 
One of the most difficult challenges in assessing secondary cancer risks from large 
epidemiologic studies is that radiotherapy techniques are quickly changing and evolving. 
These technical advances have greatly impacted dose delivery methods, resulting in dose 
distributions within the patient that may vary greatly from one treatment modality to 
another. These improvements have also impacted the likelihood of acute and late 
radiation-associated toxicities. For example, more conformal techniques have led to 
better-tolerated treatments with fewer side effects, it may be expected that there are 
similar impacts on late effects. However, without long-term epidemiologic studies, it is 
difficult to assess the actual impact. 
Despite the lack of long-term studies, novel radiotherapy techniques are being 
adopted and utilized to treat patients. However, it is critical to use accurate absorbed 
dose estimates and keep track of patients and investigate the occurrence of short-term 
and long-term secondary toxicities and morbidities, including quality of life. One of the 
most notable recent advances in radiation treatment is the increased utilization of proton 
therapy, which has the ability to concentrate radiation dose in the target volume while 
sparing normal tissues by reducing exit doses [28-30]. Because it is such a new 
modality, there is a lack of methods to accurately reconstruct proton therapy treatment 
dose and assess the risks of long-term adverse effects, such as cancer, that may develop 
due to the scatter radiation. The methods in this study will be used to both estimate organ 
dose received from proton therapy and to use the current risk models to calculate the risk 
of cancer incidence.   
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Epidemiologic studies investigating the associations of radiation dose on 
secondary outcomes relies on accurate reconstructions of radiation therapy dose received 
by the patient during treatment. Because dose estimates are based on patient-specific 
treatment parameters, the quality of retrospective data depends on how complete and 
accurate the treatment records are for each subject.  
Varying studies will require different methods of dose estimation, depending on 
the available information and available dosimetry methods. For large epidemiologic 
studies, there are several methods established to estimate dose from conventional 
therapy. Many studies reconstructing dose received during conventional radiotherapy 
utilize the Stovall et al. method [8]. This collection of methods uses various approaches 
to reconstruct patient dose, such as coupling water phantoms and thermoluminescent 
dosimeter (TLD) measurements with anthropomorphized anatomies.  
Methods used for estimating absorbed dose to organs inside and outside of the 
defined treatment volume may vary greatly between treatment modalities and may 
require archival data collection, abstraction and review, and phantom measurements to 
simulate past exposure conditions [8]. Analytical dose algorithms typically used in 
treatment planning systems (TPS) provide excellent dosimetric accuracy inside the 
therapeutic field. In fact, TPS dose may be sufficient for epidemiological studies [31, 32] 
if the necessary dose is inside the treatment field and there is no complicated 
heterogeneous anatomy surrounding the region. In such cases, epidemiologic studies of 
radiotherapy may not require any additional dosimetry. 
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However, radiation to normal tissue and organ dose outside of the immediate 
radiation field has only recently been becoming considered to be more and more 
important due to concerns of long-term adverse effects [13]. Consequently, a growing 
number of studies now require accurate dose estimates of the areas far away from the 
tumor area. In these regions, treatment planning systems severely underestimate 
scattered radiation and are not suitable for research into effects of the low dose radiation 
in those regions [33]. Since the dose in these regions cannot be estimated with 
confidence [34-37]; therefore, alternative methods estimating organ dose need to be 
pursued. 
There are three major components of absorbed dose outside treatment beams 
from external beam radiotherapy which, for conventional radiotherapy are not accurately 
accounted for in current TPS dose calculations:  
(1) radiation leakage through the head of the machine,  
(2) scatter off of the beam collimators, and  
(3) scatter within the patient from the primary beam [8].  
When additional information is available, more accurate dose reconstruction methods, 
such as Monte Carlo simulations, are used. For example, Lee et al. [38] developed a 
method to couple computation phantoms and the x-ray voxel Monte Carlo code 
(XVMC). Joosten et al. [39] calculated organ-specific out-of-field doses after IMRT for 
breast cancer treatments using whole-body CT scans coupled with in-house Monte Carlo 
models.  
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1.5 DOSE FROM CONVENTIONAL PHOTON VS PROTON THERAPY  
Conventional external beam radiotherapy concentrates the dose in the tumor while 
minimizing dose to normal tissue by distributing the dose across normal tissue from 
different fields. In photon therapy, the dose distribution reaches its maximum in the body 
near the beam entrance and is then followed by an approximately exponential decrease 
in dose deeper into the body as shown in the illustrative Figure 1. 
 
 
Figure 1. Comparison of dose deposition from an external 6 MV photon beam and 
an illustrative pristine Bragg peak from a mono-energetic beam and a spread-out 
Bragg peak (SOBP) from a multi-energy beam treatment. 
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1.6 ADVANTAGES OF PROTON THERAPY 
The advantage of utilizing proton therapy is the potentially improved dose 
conformation to the tumor and a smaller dose to normal, normal tissue compared to that 
due to conventional radiotherapy treatments. Due to the physical properties of protons, it 
is possible to plan treatments with an integral dose that is better than the best 
conventional treatment modalities. Currently, some of the most common types of these 
therapies are 3D conformal radiation therapy (3D-CRT), intensity modulated radiation 
therapy (IMRT), and volumetric arc therapy (VMAT) [40]. Figure 2 is an illustrative 
figure comparing the dose deposition from a photon therapy treatment plan and one from 
proton therapy. 
 
 
Figure 2. Illustrative difference between photon therapy and proton therapy dose 
delivery demonstrating why integral dose from proton therapy can be as little as a 
third from conventional photon therapy. 
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Due of their physical properties and use of fewer fields, integral dose from 
proton therapy can be as little as a third of that from conventional therapy and a half of 
that from x-ray IMRT [41]. This is especially of great interest in pediatric patients who, 
as compared to adults, receive a greater dose to their healthy organs on average due to 
their physical smaller size [42] and higher sensitivity to radiation-induced cancers by a 
factor of at least 10 [43].  
On average, protons are slightly more biologically effective than photons, with 
an average Relative Biological Effectiveness (RBE) during treatment estimated to be 1.1 
[44]. Therefore, a lower physical dose may be used to cause the same biological effect 
[45]. Due to the potential benefits of proton therapy for treating solid tumors, it has been 
growing in popularity and use worldwide. As of November 12th, 2017, there are 26 
proton therapy centers in the US and 11 more under construction [46]. In some cases, 
proton therapy may be the only acceptable treatment in curable children because of its 
more favorable dose distribution characteristics around a tumor. 
However, proton therapy is still a relatively new modality of cancer treatment and 
it has significant issues to overcome. Moreover, there have not been many epidemiologic 
studies showing improvements of clinical outcomes in patients receiving proton therapy 
when compared to conventional photon modalities. This requires immediate attention. 
Epidemiologic studies looking into long-term effects due to proton therapy and 
comparing it to late-effects from more conventional photon therapy are in their initial 
stages at the NCI requiring full body organ dose estimations from novel treatment 
modalities. 
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1.7 DOSE TO NORMAL TISSUES  
Scatter radiation resulting in dose to normal tissues during photon therapy is 
usually in the form of photons and scattered electrons. However, treatments using very 
high energy photons can potentially generate neutrons through photonuclear (K, V) 
interactions in the patient and accelerator’s treatment head [47] and should be 
considered. Photons require energies greater than 8-10 MeV (~12-15 MV) to physically 
be capable of producing neutrons and it has therefore been standard to avoid higher-
energy treatments. However, for certain cases, they are the best course of action. For 
example, for breast treatment it has been shown optimal to treat with a combination of 6 
MV and 18 MV [48]. With newer treatment methods and increasing interest in low dose 
received by normal tissues, there has also been growing interest in neutron dose from 
these high energy photon treatments [47, 49, 50].  
During proton therapy, neutrons are always produced and are the main component 
of secondary scatter dose to normal tissue. As such, for a 70 Gy treatment from a course 
of proton therapy treatment for pediatric patients, the neutron dose could potentially be 
equivalent to up to ~30 CT scans [51]. This is due to the fact that whenever protons pass 
through material and tissues, there is a probability that they will undergo a (W, V) nuclear 
reaction producing neutrons. And, because neutrons can be highly biologically effective, 
even a small dose may cause undesired secondary effects in the patient, worst of which 
is cancer [18]. Following studies into preliminary evaluations of dose being possibly 
inaccurate – especially in heterogeneous regions – and possible long-term effects from 
unaccounted secondary particles produced during proton therapy, there has been an 
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increase in interest of accurate dose reconstruction of dose from protons and secondary 
particles produced and creating a dose-cancer induction risk assessment from proton 
therapy treatments [18, 52, 53].  
During proton therapy, neutron production occurs both inside and outside of the 
patient with the number of neutrons produced during a treatment depending on the 
amount and type of physical material traversed by the proton on the way to the tumor. 
As such, the number of neutrons produced during a treatment varies greatly, depending 
on a variety of factors including the proton treatment type, patient anatomy, tumor 
location, and the treatment plan.  
 
1.7.1 Secondary Neutron Dose  
During passive scattering, the majority of secondary neutrons are produced in the 
treatment head [54] while spreading the beam out to meet the tumor-specific 
conformality, as is illustrated in Figure 3. 
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Figure 3. Illustration of typical passive scattering system 
 
Passive scattering methods generate the largest quantity of neutrons by producing 
them in the treatment nozzle, scattering foils, apertures, and collimators [55]. Neutron 
dose from such scattering is a growing concern with secondary doses because they may 
be as high as those from photon therapies such as IMRT [56]. According to previous 
studies, under passive scattering conditions, secondary neutron dose varies from 0.1 mSv 
to 8 mSv per delivered proton dose (Gy) to the target area. This is affected by the nozzle 
settings such as beam energy, the scattering material, range modulation, use of snout, 
aperture, and other additional material.   
Modeling passive scattering treatments with Monte Carlo methods therefore 
requires simulating the full “treatment head”. To do this, blueprints and measurements 
taken at each proton treatment center are needed to create a facility-specific Monte Carlo 
simulation environment [53, 57]. This is due to the fact while the protons passing 
through scatterers conform the beam shape to cover a larger treatment, the beam also 
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undergoes nuclear	(W, V)	interactions with the material it passes through producing 
secondary dose in the form of neutrons. In the treatment head, it is typical for the proton 
beam to interact and scatter off of lead, brass, tungsten, and aluminum. A comparison 
between the cross-sections for	(W, V)	in common material used in the treatment head (Al, 
Pb, W) and inside the patient (C, N, O) as a function of incident proton energy were 
obtained from JANIS [58] is shown in Figure 4. 
 
 
Figure 4. Cross sections for proton-neutron nuclear interactions with elements 
inside the patient (C, N, O) and external to the patient, from the treatment head 
(Al, W, Pb). 
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1.7.2 Active scanning proton therapy 
This work, however, focuses on the newer and growing in popularity, active or 
“spot” scanning method of proton beam delivery. While passive scattering matches the 
profile of the tumor by spreading the beam out by increasing the amount of nuclear 
interactions (and neutrons produced), active scanning instead uses electromagnets to 
direct the proton beam [59] and “paints” the dose, delivering dose pockets or “spots”, as 
is illustrated in Figure 5, increasing proton dose conformality and reducing the 
secondary neutron dose.  
         
Figure 5. Illustration of typical active scanning system 
 
Though the number of neutrons produced is reduced significantly during active 
scanning, there are still neutrons produced within the patient. During active spot 
scanning, the great majority of neutrons are produced within the patient.  
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1.7.3 Low-dose scatter radiation from proton therapy 
Recently there has been growing interest in the dose received by normal tissue in 
the out-of-field regions from scattered radiation from proton therapy treatments. A 
growing number of publications have been establishing and using methods to calculate 
secondary organ dose from proton therapy [17, 32, 52, 53, 60-64] and comparing it to 
other treatment modalities [39, 65, 66]. As shown previously, protons undergo a 
different set of physics compared to photons used during conventional treatments 
resulting not only in a different dose deposition, but also a different set of secondary 
radiation, requiring a more sophisticated method of dose estimation.  
To quantify the dose and risks due to neutrons, several studies have been 
published showing various experimental and simulation setups. Neutron dose has been 
shown to be age and stature dependent and to fall off rapidly as a function of distance 
from the target [42]. At Massachusetts General Hospital, Jiang et. al. [59] simulated 
organ-specific patient doses due to secondary neutrons during proton therapy utilizing an 
image-based whole-body voxelized phantom of the Visible Human Project using a 
Geant4-based Monte Carlo code. Zacharatou Jarlskog et al. [51] calculated dose to 
organs away from the target using age-dependent phantoms considering eight typical 
radiation fields allowing for a systematic study of equivalent doses as a function of field 
parameters showing that neutron doses to specific organs depend considerably on the 
patient's age and body stature. Neutron dose from proton therapy was compared to 
secondary out-of-field photon dose from IMRT by Athar et al. [65] using Monte Carlo 
transport methods coupled with adult and pediatric voxel phantoms.  
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However, there have still not been any studies on long-term effects due to the 
low doses that normal, healthy tissues receive. Moreover, there are no established 
methods to carry out facility and treatment-specific Monte Carlo organ dose 
reconstruction of proton therapy treatments for large-scale epidemiologic studies. This 
work investigates and establishes one of the methods to be used in NCI epidemiological 
studies to reconstruct doses from scanning proton therapy treatments and such method is 
applied to measurements from the Maryland Proton Treatment Center, creating the 
facility-specific beam model which can be used for further dose reconstruction of 
patients at this facility just from the patient DICOM files. 
 
1.7.4 Proton risk calculation studies 
While there are no established method for large-scale epidemiologic studies 
looking into long-term secondary effects for proton therapy patients, there are studies 
using risk models, such as BEIR VII [10], that estimate the associated risk for 
developing a second cancer from scatter radiation from proton therapy treatments based 
on multiple fields, varying treatments, varying age, and other parameters. 
In a recent article by Newhauser et al. [67], the estimated risk of second cancer 
following a craniospinal (CSI) treatment using adult male phantoms was calculated for 
passively-scattered and scanned-beam proton treatment units. It was found that the total 
lifetime risk of second cancer due exclusively to stray radiation was 0.8% for the 
scanned proton beam treatment. Considering the therapeutic and stray radiation fields, 
the risk of second cancer from intensity-modulated radiation therapy and conventional 
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radiotherapy photon treatments were 7 and 12 times higher than the risk associated with 
scanned-beam proton therapy, respectively [67]. 
For a brain treatment with passive scattering proton therapy, the main 
contributors to the neutron-induced risk have been shown to be neutrons generated in the 
treatment head, resulting in most lifetime risks to be < 1% for a 70-Gy treatment [55]. A 
study by Asthar et al. [42] looked into CSI treatments showing that, for an 8-year-old 
female patient treated with a spinal proton therapy field, the highest radiation-induced 
lifetime cancer incidence risks were for breasts of 0.71%, lungs of 1.05% and the rectum 
of 0.60%. For an 11-year-old male patient treated with a spinal field, the bronchi and 
rectum showed the highest risks with a 0.32% and 0.43%, respectively.  
Risks of secondary effects from radiotherapy differ depending on several patient 
characteristics. Age and gender both need to be considered during treatment. Young 
patients are subject to significantly greater risks than are adult patients because of the 
geometric differences and age dependency [42, 55]. In addition, the younger the patient, 
the higher the dose deposited in critical organs due to neutrons [51]. Because of these 
factors, the leading risks from radiotherapy for female pediatric patients is breast cancer. 
For males, the risks of lung cancer, leukemia, and thyroid cancer were significant for 
pediatric patients. In contrast, leukemia was the leading risk for an adult [55].  
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1.7.5 NCI planned studies 
During treatment, late effects are not the primary concern, as the focus is on 
“curing” the patient, which is defined as complete remission for 5 years or more by some 
protocols. However, because of technological improvements resulting in patients living 
longer, the advantages of proton therapy need to be scrutinized through epidemiologic 
studies looking at long-term patient benefits, including quality of life. The National 
Cancer Institute (NCI) plans to conduct such studies, but first needs to develop the 
capability to calculate out-of-field absorbed doses from proton treatments, on which this 
work is focused.  
The NCI will be conducting multiple studies assessing the long-term effects of 
proton therapy from multiple proton therapy centers. The methodology described in this 
section will be used in the future to simulate doses from these proton therapy centers. 
The use of dose provided from treatment planning systems may not be sufficiently 
accurate because the algorithms make approximations which may result in uncertainties 
and do not include out-of-field doses from neutrons [68].  
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1.8 OBJECTIVES OF THE PRESENT WORK 
This work extends the current NCI dose reconstruction methods limited to x-ray 
radiotherapy by adding active scanning proton therapy dose reconstruction capabilities. 
The first objective of this work was to overcome a common issue in dose reconstruction 
studies of lacking full-body anatomy needed for Monte Carlo simulations by combining 
the available patient anatomy from CT images with phantom anatomy. The second 
objective was to establish a method to estimate the full-body organ doses received by the 
patient during proton therapy using the Monte Carlo code, TOPAS. To do this, neutron 
transport and scatter was validated by comparing results obtained from TOPAS with 
experimental measurements and with the well-established Monte Carlo N-Particle 
(MCNP) transport code. Computational tools were established to translate treatment 
planning system output data into TOPAS input parameter files using measurements from 
the Maryland Proton Treatment Center. The final objective was to simulate proton 
therapy on pediatric phantoms and calculate organ dose and to calculate the secondary 
cancer risk due to proton therapy based on the BEIR VII risk models. 
 
1.8.1 Lack of full patient anatomy 
Advances in radiological imaging combined with modern radiotherapy have 
made the delivery of radiation to the intended target more accurate. Nonetheless, even 
the most careful treatment planning will still deliver radiation dose to nearby normal 
tissues. To overcome the challenges of lacking a) efficient dose reconstruction methods 
for large-scale patient cohorts and b) the lack of full radiological images representing 
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patient anatomy, Lee et al. [38] developed the methods to reconstruct organ doses for 
patients undergoing photon radiotherapy using a series of ICRP computational phantoms 
shown in Figure 6 coupled with TPS and radiotherapy-dedicated Monte Carlo transport 
methods. These include the use of DICOM images of contoured hybrid computation 
phantoms and commercial TPS and X-ray Voxel Monte Carlo (XVMC) code for the 
simulating dose in-field and out-of-field. This work was later extended to use a full, 
height-and-weight-specific library of phantoms [69].  
 
   
Figure 6. Family of anthropomorphic phantoms with ages ranging from New Born 
to Adult male and female. 
 
1.8.2 Dose reconstruction from proton therapy treatments 
 A method to reconstruct doses from proton therapy treatments based on patient 
data and facility-specific measurements using the Monte Carlo simulation code Tool for 
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Particle Simulation (TOPAS) [70] is established in this work. The active scanning beam 
modeling method includes utilizing patient-specific and treatment-specific data for 
accurate dose simulations. This method will later be extended at the National Cancer 
Institute to model other proton treatment facilities. 
 
1.8.3 Risk calculation of proton therapy treatments 
Risk estimates are often determined from either effective whole-body doses or 
organ-weighted dose. In fact, the tissue weighting factors used by the NCRP and ICRP 
for the effective doses are gender-and age-averaged values [13]. However, risk 
calculations from active scanning proton therapy are carried out on age-dependent, 
organ-specific risks because baseline risks and cancer occurrences are site-specific. 
Especially with a treatment such as proton therapy that results in specific regions with 
high doses within the patient, this may be more meaningful than average total-body risk 
estimates.  
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2 METHODS AND MATERIALS 
2.1 ANATOMY EXTENSION METHODS FOR OUT-OF-FIELD DOSIMETRY  
Improved knowledge of the relationship between organ dose received during 
radiotherapy and secondary effects is critical for the optimization of treatment 
techniques and the development of preventative measures for mitigating toxicities. 
Epidemiologic investigation is one important way to assess the risk of late effects 
following radiotherapy, and accurate organ dosimetry is a key component of such 
analysis. Dosimetry for epidemiologic studies, however, poses several unique 
challenges.  
First, the dose calculation methods need to cover regions beyond the target and 
adjacent tissue which are not often considered as part of standard clinical practice. The 
methods must also be simple and fast enough so that they can be applied to a large 
cohort. To address these issues, previous epidemiologic studies have relied on analytical 
dose calculation methods based on physical measurements in water phantoms [8, 13, 
71]. More recently, advanced analytical methods [72, 73] and streamlined Monte Carlo 
radiation transport methods [38, 74] have been proposed. 
Second, for retrospective epidemiologic studies, there is often large uncertainty in 
the patient anatomy because radiological images are not always accessible for patients 
who were treated many years ago or may be too expensive to retrieve. Furthermore, even 
when computed tomography (CT) images are available, it is often the case that the scan 
coverage does not include all the anatomy of interest. CT scans conducted for 
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radiotherapy planning typically cover only a portion of the body near the target volume. 
However, epidemiologists are often also interested in the dose received by normal 
tissues located further away [75]. The tissues and organs of interest may be located 
completely outside the CT scan coverage or may be only partially included. One way to 
overcome this challenge is to use whole-body computational human phantoms [76, 77] 
which provide extended anatomy for calculating dose to out-of-scan organs. However, 
there will inevitably be a difference between the anatomy of the computational phantom 
and the patient. Organ dose calculations need to be highly individualized, and for some 
applications, small anatomical differences can result in substantial differences in 
absorbed dose. This is especially true for radiotherapy because of the steep dose 
gradients involved. 
An important research question is how computational phantoms can be adjusted to 
a specific individual to improve dosimetry methods. It was hypothesized that organ 
dosimetry estimates can be improved by incorporating partial-body CT images, when 
available, into the computational phantom. To test this hypothesis, an automated method 
was developed for extending a partial-body CT to whole-body anatomy for cases where 
the organs of epidemiologic interest reside outside the available CT scan range. This 
method was called Anatomically Predictive Extension (APE) and the resulting patient-
phantom combination is called an APE phantom. 
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2.2 ANATOMICALLY PREDICTIVE EXTENSION (APE) METHOD 
Anonymized chest-abdomen-pelvis (CAP) CT scans of five patients were retrieved 
from the National Institutes of Health (NIH) Clinical Center in Digital Imaging and 
Communications (DICOM) format. The in-plane resolution of the images ranged from 
0.8203 cm × 0.8203 cm to 0.9375 cm × 0.9375 cm. The slice thickness of the CT images 
was 0.5 cm for all patients. The CAP CT scans cover nearly all the organs of 
epidemiologic interest starting at the lung apices and extending to the symphysis pubis. 
The average age of the five patients was 52 years (45 – 58 years). The average height 
and weight were 176 cm (162 – 193 cm) and 85 kg (68 – 104 kg) with the body mass 
index (BMI) ranging from 24 to 30 kg/m2. The CT images were imported into an Eclipse 
treatment planning system for the contouring of major organs. Subsets of the CAP CT 
scans were created for testing the APE method, with the full CAP CT scans being used 
as ground truth. Two partial-body image subsets were created from the CAP CT scans: 
one representing a chest CT (lung apices to cost phrenic angle) and the other 
representing an abdominal CT (diaphragm to symphysis pubis). 
 
2.2.1 Computational phantom selection 
The APE method substitutes the missing patient anatomy with that of a 
computational human phantom selected from a library of phantoms developed at the 
NCI in collaboration with University of Florida [69]. The library consists of a total of 
351 pediatric and adult phantoms with different heights and weights to represent the US 
population. The height and weight of the adult male phantoms ranges from 160 to 190 
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cm and from 50 to 140 kg, respectively. These whole-body phantoms were developed 
based on patient CT images and contain over 100 different organs and tissues. The 
polygon-mesh phantoms used in this work were voxelized to match the resolution of the 
five patient CAP CT scans described above. The voxelized phantoms were then 
converted to DICOM CT images and a corresponding DICOM-RT structure file 
containing the phantom organ contours. The methods for generating these files were 
described in a previous work [38]. For this work, computational phantoms from the 
library most closely matching each of the five patients were selected based on available 
data from the medical records such as age, gender (in this study, male), height, and 
weight. The arms of the phantoms were removed before voxelization to approximate CT 
patients who have their arms raised above their shoulders (i.e. outside the CT scan 
range). 
 
2.2.2 Identification of the optimal merge location  
An algorithm was developed to automatically select the optimal axial z-position 
in the phantom where the patient’s partial-body CT can be inserted to create an 
approximately continuous whole-body anatomy. This was achieved by generating two-
dimensional anterior-posterior (AP) masks of the patient and phantom skeletal 
structures. The skeletal masks were created by applying a threshold to the CT image 
pixels based on their assigned Hounsfield Unit (HU). Pixels in the range of 285 HU to 
3500 HU were selected to capture most skeletal structures. The masks were normalized 
to have a value of 1 in the skeleton and a value of 0 elsewhere.  
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 The optimal merge location was selected as that resulting in maximal overlap 
between the phantom and patient skeletal masks. A global search is conducted by 
scanning the patient skeletal mask across the phantom skeletal mask in both the lateral 
and axial directions. A Dice similarity coefficient is calculated for each possible 
alignment of the masks. When the upper-left hand pixel of the patient skeletal mask is 
located at pixel index position (X, Y) relative to the phantom skeletal mask, the Dice 
Similarity Coefficient, !"#, is calculated as, 
 !"#(X, Y) = 2[(Fℎ(X, Y) ∩ F9)[^Fℎ(X, Y)_ + [(F9) (11) 
where, [ is an operator yielding the number of pixels of value 1 in a binary mask,	F9 the 
two-dimensional (2D) skeletal mask of the patient derived from the patient’s partial-
body CT, and Fℎ(X, Y) is the 2D skeletal mask of the whole-body phantom cropped to 
the size of the patient mask so that the pixel at index coordinate (X, Y) is in the upper-left 
hand corner. The mask Fℎ(X, Y)	is padded with zeros as necessary so that it is the same 
size as F9. The !"# can range from 0 to 1, where a value of 0 represents the case where 
masks do not overlap at all and a value of 1 represents the case where the masks overlap 
completely. The !"# will reach a maximum at some optimal index coordinate (X∗, Y∗). 
The optimal z-position, Y∗, is selected as the location for inserting the patient images into 
the phantom. The optimal lateral coordinate, X∗, provides some information on how to 
align the skeleton of the patient and phantom in the lateral direction. However, it was 
opted instead to use the outer dimensions of the patient and phantom for the lateral and 
anteroposterior alignment as described in the next section. 
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 The reliability of our method for registering the phantom and patient anatomies 
was evaluated using the five patient CAP CT scans. A total of 23 subsets of the CAP CT 
image stacks which were 20 cm in axial length were generated at axial increments of 2 
cm, starting from the lung apices to the symphysis pubis (0 to 20 cm, 2 to 22cm, 4 to 24 
cm, etc.). The optimal merge location for each of the CT subsets was calculated using 
the method above. The axial position, Y∗, selected for the CT subsets was then compared 
to the expectation that they should incrementally increase by 2 cm (0, 2, 4, 6 cm, etc.) as 
constructed for the five patients. 
 
2.2.3 Merging patient and phantom anatomy 
The patient and phantom anatomies are merged at the selected axial position Y∗ 
by overriding the phantom anatomy with that of the patient. A bounding-box registration 
method was used to reduce discontinuities between the phantom and the patient. The 
phantom portions are linearly scaled in the lateral (X) and anterior-posterior (`) direction 
to match the outer contour dimensions of the patient as measured on the first and last 
image in the patient’s partial-body CT stack. The phantom image stacks appended above 
and below the patient’s partial-body CT image stack are scaled independently and 
aligned at the center of the bounding boxes.  
The tumor and the selected organs at risk in the patient are typically contoured by 
manual segmentation as part of the radiotherapy treatment planning. The phantoms used 
in this work have the advantage that they come pre-contoured with over 100 different 
organs and tissues. Our anatomy extension method reads the pre-existing DICOM-RT 
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structure files of the patient and combines them with those of the phantom, overriding 
the phantom contours where necessary. The patient and phantom structures are matched 
through the use of standard naming conventions. The same translation and scaling 
factors applied to the phantom images are applied to the phantom contours. For instance, 
the upper half of the patient’s liver may be contoured from the partial-body CT images. 
The lower half of the liver will then be taken from the phantom and the two structures 
will be combined into a single liver structure in the final merged APE phantom. 
 
2.2.4 Automated scripts for anatomy extension 
An in-house application was written in the Python computer language to 
automate the APE method. A key feature of this software is that it reads and writes files 
in DICOM format. The input to the software is the patient’s partial-body CT and a 
corresponding DICOM-RT structure file containing the patient’s radiotherapy target and 
normal tissue contours. The output of the software is a directory containing the DICOM 
CT images of the whole-body APE phantom and a DICOM-RT structure file containing 
the APE phantom organ contours. These files can then be used as the input for dose 
calculation tools such as a commercial treatment planning. The workflow of the APE 
method is summarized in Figure 7.   
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Figure 7. Workflow of the anatomically predictive extension (APE) method. 
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2.2.5 Validation of APE Method in illustrative radiotherapy 
When a patient’s CT images are unavailable, and height and weight are 
unknown, the best option for dose reconstruction is to use a reference phantom as a 
surrogate for the unknown anatomy. In this work, my aim was to test whether the organ 
doses calculated using APE phantoms would be more accurate than those calculated 
using a reference phantom. Two idealized cases representing chest and prostate 
radiotherapy treatments were considered. Organ doses were calculated for simple chest 
and prostate irradiations that were planned on a reference computational phantom [78] 
(assumed patient geometry if no CT images are available), the APE phantoms (patient-
phantom hybrid given a partial-body patient CT), and the full patient CAP CT images 
(ground truth). 
As the normal tissues of interest are located away from the primary radiotherapy 
fields, a methodology to calculate out-of-field organ dose that was previously published 
by the Radiation Epidemiology branch was selected [38]. This method uses the X-ray 
Voxel Monte Carlo (XVMC) code as the dose calculation engine [79]. All cases were 
transferred to an Eclipse treatment planning system. A certified medical physicist 
created simple chest and prostate treatment plans on the patient CAP CT scans (Figure 
8). The same treatment plans were then copied to the reference phantom and APE 
phantoms. The mean organ dose received by the heart, left and right lungs, liver, 
stomach, bladder, and prostate was calculated for the idealized radiotherapy treatments. 
Sufficient particle histories were simulated to ensure that the Monte Carlo statistical 
error on the organ dose estimates was negligible (<1%) in all cases. 
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Figure 8. Screenshots of the chest irradiation (a) and prostate irradiation (b) taken 
from the Eclipse treatment planning system. 
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2.2.6 Patient CT and selected phantoms 
Figure 9 shows the chest and abdominal CT images extracted from the CAP CT 
scans of the five patients having different heights and weights. The body size-matched 
adult male computational phantoms are shown to the left of the patient CTs in increasing 
order of BMI. 
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Figure 9. The chest and abdominal CT image sets extracted from the full chest-abdomen-pelvis (CAP) CT scans for the 
five patients. The patients have different BMIs which range from 24 to 30 kg/m2. To the left of the patient images are 
the computational. 
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2.2.7 Selection of optimal merge location 
The performance of the algorithm for determining the optimal merge location for 
the five patients is shown in Figure 10. The distance between the lung apices of the 
patient and the top of the partial-body CT extracted from the CAP scans is plotted on the 
x-axis and increases from 0 to 44 cm in 2 cm increments. The corresponding optimal 
merge location,	"∗, for each subset of the CAP scan are shown on the y-axis relative to 
the axial location of the lung apices in the phantom. We expect that the graph would 
show a line to identity if the algorithm perfectly maps the patient skeletal anatomy onto 
the phantom. Overall, the selected merge locations for the five patients show good 
agreement with the original anatomical locations. As the mapping process is based on 
the bony structures, we found that it is sensitive to the postures of the patients and 
phantoms. The least accurate portion is in the 0 to 10 cm range, which is attributed to 
differences in scapular rotation. The patients have their arms positioned above their 
shoulders, while the phantoms originally had their arms down at their side. The slope of 
the lines in Figure 10, do deviate from 1. This indicates that even though the patient and 
phantoms have similar heights, there can still be systematic differences in the distances 
between skeletal landmarks. 
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Figure 10. Comparison of the distance of the partial CT skeletal mask (x-axis) with 
the distance of the merge location selected by the APE algorithm (y-axis) for the 
five patients. 
0
10
20
30
40
50
60
0 5 10 15 20 25 30 35 40 45 50
Di
st
an
ce
	o
f	S
el
ec
te
d	
M
er
ge
	Lo
ca
tio
n	
on
	P
ha
nt
om
s	f
ro
m
	L
un
g	
Ap
ice
s	(
cm
)
Distance	of	Partial	CT	from	Lung	Apices	of	Patients	(cm)
Patient	1
Patient	2
Patient	3
Patient	4
Patient	5
 43 
 
The skeletal mapping procedure for Patient 3 with a height of 193 cm is 
illustrated in Figure 11. Convolution of the skeletal maps of the chest CT and the whole-
body phantom was performed and the largest %&'	was calculated as a function of axial 
position "	is plotted on the left in a solid line. The global maximum %&' was 0.66 at an 
axial position of 162 cm measured from the feet of the phantom. The case of the 
abdominal CT (Figure 11) had a global maximum %&' of 0.78 at an axial position of 
125 cm. In both cases, the %&' reached local maxima at different axial positions (e.g., 
around 120 cm, pelvis region, for the chest CT and around 175 cm, clavicle region, for 
the abdomen CT) indicating that this algorithm cannot resolve this issue.  
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Figure 11. An example of the mapping process for Patient 3. The largest Dice 
Similarity Coefficient, ()*,	calculated as a function of the axial position (left), the 
skeletal mask of the selected phantom (center), and the skeletal masks of patient for 
the chest (a) and abdominal (b) cases. 
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2.2.8 APE whole-body phantom 
An example of APE phantoms generated from chest and abdominal CT scans 
take from the full CAP CT scan of Patient 5 is shown in Figure 12. The organ contours 
for the patient and APE phantom are also shown. The organs at the boundary between 
the anatomies of the patient and the phantom (such as the liver and the stomach) show 
imperfect, although sometimes remarkably great, continuity. The organ contours for the 
patient and phantom are combined so that the mean dose received by the merged organs 
(e.g., the liver or stomach) can be calculated. 
 
Figure 12. Example APE phantom generated from chest and abdominal CT scans 
for Patient 5. The chest CT-based APE phantom (left), the original full torso CT of 
the patient (center), and the abdomen CT-based APE phantom (right). 
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2.3 MONTE CARLO DOSE SIMULATIONS 
It has been shown that Monte Carlo simulations, though computationally more 
expensive, are greatly superior to analytical methods for dose calculations of x-ray [80] 
and especially for particle treatments such as protons [81]. In addition, the use of Monte 
Carlo simulations is needed because TPS may be highly inaccurate in heterogeneous 
regions [38], does not calculate out-of-field dose, and does not account for neutrons. The 
Tool for Particle Simulation (TOPAS) Monte Carlo platform [82] has been chosen 
because it is specifically designed for proton therapy and other radiation therapy 
simulations. The underlying GEANT4 has been tested and is well-benchmarked [83-88]. 
However, it has many components and settings making it important to validate TOPAS 
as a whole to confirm its accuracy, especially in particle scatter and out-of-field dose. 
While working on validating TOPAS, it was also necessary to work with the developers 
to fix underlying issues with TOPAS.  
In the following sections, particle scatter simulations from TOPAS are compared 
with measurement and a more established neutron transport code and a generic method 
is investigated to be used in epidemiologic studies that requires reconstructing dose from 
facility-specific active scanning proton therapy treatment. Then, a beam model for the 
Maryland Proton Treatment Center (MPTC) proton beam facility is created, organ doses 
are calculated for two treatment plans, and the associated risks are calculated. 
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2.3.1 TOPAS simulation environment 
The number of processes, models, and cross-section data available in GEANT4 
makes it not only extremely flexible but also a very complex tool to configure. TOPAS  
has been chosen as the package to best simulate proton therapy treatments [70] because 
it was designed specifically for particle therapy simulations and its ease of use. There are 
numerous versions and GEANT4 parameters that can be adjusted, depending on the 
application type. For these studies, the TOPAS simulation was based on Geant4 
v10.2.p01 using the default settings of TOPAS combined with settings based on 
Zacharatou et al [89]. This includes the physics list containing the Geant4 modules: 
g4em-standard_opt4, g4h-phy_QGSP_BIC_HP, g4decay, g4ion-binarycascade, g4h-
elastic_HP, and g4stopping. The QGSP_BIC_HP portion of the physics list uses 
GEANT4 binary cascade for neutrons with energies below 10 GeV along with the data 
driven high precision neutron package, NeutronHP, to transport neutrons below 20 MeV 
down to thermal energies. These physics settings were the same for all calculations in 
this dissertation work. 
 
2.3.2 Benchmarking TOPAS scatter simulations  
The biggest concern for long-term effects resulting from scatter radiation 
produced during proton therapy is dose from scattered neutrons [90], which may travel 
far from the target site and have varying energy and relative biological effectiveness 
(RBE). The RBE of neutrons is dependent on the neutron energy [91], and therefore how 
TOPAS simulates neutron scatter also needs to be benchmarked. To do this, TOPAS 
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simulations were created using a simple geometry setup, compared experimentally and 
with Monte Carlo N-Particle code (MCNP). MCNP is a well-validated, general-purpose 
code that is used for the transport of particles and has been applied to a multitude of 
areas such as radiation protection and dosimetry, detector design, radiation shielding, 
medical physics [92].  
A simple geometry was developed to be simulated in TOPAS and MCNP, and to 
be physically measured at the National Institutes of Standards and Technology (NIST) in 
Germantown, Maryland. The setup includes a neutron source, a cylindrical phantom, and 
detectors to be placed centered in phantom and irradiated with a neutron source as 
shown in Figure 13. 
 
 
Figure 13. Setup for validation TOPAS scatter simulations. 1) Proton simulations: 
source monoenergetic, 150 MeV and ICRP adipose tissue phantom; and 2) Neutron 
simulations: Californium-252 source and polyethylene phantom. 
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For the neutron source, an isotropic NIST Californium-252, minimally 
moderated with D2O. The emission rate of the source on 2/25/2016 was 1.762E7 n s-1, 
producing a dose equivalent rate of 0.7662 mSv/hour at 50 cm. A Cf-252 source has an 
average energy of 2.3 MeV. To recreate the spectrum with simulations, an unmoderated 
Cf-252 neutron energy spectrum was obtained from ENDF/B-VII. The Neutron Sources 
and Neutron Dosimetry Calibrations group at NIST also provided MCNP simulation 
results for the lightly moderated source, as can be seen in Figure 14, comparing a 
moderated and unmoderated spectrum at 50 cm for the source. This comparison 
confirmed that the neutron spectrum as measured by the bubble detectors from a 
moderated source would be indistinguishable from that of an unmoderated Cf-252 
energy spectrum. 
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Figure 14. MCNP simulations of the neutron spectrum at 50 cm from the source, 
showing that the lightly moderated and unmoderated spectrum differ less than the 
bubble detectors could account*  
 
Though several detectors provide better energy resolution, bubble detectors [93, 
94] were chosen for these measurements because of their insensitivity to gammas, ability 
to provide a neutron spectrum, and their small size lending them to provide good spatial 
resolution. This potentially allows them to be used for providing a neutron energy 
spectrum with in-phantom measurements utilizing anthropomorphic phantoms for the 
neutron energy range that is most biologically effective. Each bubble detector (shown in 
                                               
* MCNP calculations were performed by members of the Neutron Sources and Neutron Dosimetry 
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Figure 15) has one of 6 different energy thresholds (10 keV, 100 keV, 600 keV, 1 MeV, 
2.5 MeV, and 10 MeV) with sensitivities ranging from 4 µSv and 17 µSv.   
 
 
Figure 15. Bubble detectors with varying energy thresholds used for neutron 
energy spectrum measurements 
 
To measure the scattered neutrons using bubble detectors, each detector needed 
to be irradiated individually inside the phantom, with each irradiation resulting in at least 
300 bubbles in each energy bin for appropriate statistics. To acquire the data, 16 
irradiations were completed, each taking from 1 to 63 hours with the experimental setup 
is shown in Figure 16.  
16 mm
80 mm
10 keV 100 keV 600 keV 1 MeV 2.5 MeV 10 MeV
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Figure 16. Experimental setup at the National Institute of Standards and 
Technology showing the source at its position before it is raised for irradiation. 
 
The experimental setup was recreated within TOPAS, as shown in Figure 17, as 
well as MCNP6. In both simulations, an isotropic neutron source with the spectrum from 
ENDF/B-VII was placed at 40 cm from the center of the detector and was simulated as a 
tissue equivalent cylinder inside of a polyethylene phantom. A total of 1 billion particles 
were simulated in TOPAS by the author and 5 billion particles were simulated using 
MCNP6 by Dr. Matthew Mille at the NCI.  
For the MCNP simulations, neutrons were simulated running in mode n using a 
Californium-252 source modeled using the previously mentioned neutron spectrum and 
the poly.20t S(alpha, beta) data library [95]. The analog energy limit was set above 20 
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MeV, so in effect, analog capture was always used. The cross-sections from ENDF71x 
Library based on ENDF/B-VII.1–Based Continuous-Energy Data Tables [96] were 
utilized. The TOPAS environment is described in the previous section and shown in 
Figure 17.  
 
 
Figure 17. TOPAS simulation reproducing the experimental setup. 
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2.4 PROTON THERAPY TREATMENT MODELS 
2.4.1 Proton therapy dose reconstruction  
The National Cancer Institute (NCI) will be conducting large-scale epidemiologic 
studies to assess the long-term adverse effects due to proton therapy treatments and will 
be investigating data from multiple proton treatment institutions. The methodology 
described in this section will be used in the near future to aid in the dosimetry portion of 
such studies. Passive scattering and active scanning are two of the most common proton 
therapy treatments modalities used today and due to the difference in dose delivery, 
separate simulation methods are required. The NCI epidemiologic studies will analyze 
dose estimates from both scattering and scanning modalities, though the current work 
focuses solely on developing and investigating method to establish Monte Carlo models 
of active scanning proton therapy facilities utilizing already available reference data 
from each treatment center. 
For passive scattering, it is necessary to simulate beam interactions in the nozzle 
because the spreading, modulation, and shaping of the beam are fully determined by the 
different elements that the beam encounters in the nozzle. In contrast to passive 
scattering, during active beam deliver, only a few elements are present in the nozzle and 
they do not significantly contribute to secondary scatter radiation. For this reason, it is 
possible to model active scanning using two different approaches. The first approach to 
model the beam includes using blueprints and making measurements to create models of 
the full treatment head as is shown in Figure 18 (A). However, as mentioned previously, 
there are few elements in the nozzle that modify and interact with the proton beam, and 
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therefore the beam can also be modeled starting at the nozzle exit, as is shown in Figure 
18 (B). Such models have been created at certain institutions by simulating the 
interaction of the proton beam in the treatment head and similar models have been 
proposed for MCNPX [97] and GATE [98].  
 
 
 
Figure 18. Modeling proton therapy in TOPAS with A) modeling full treatment 
head and B) modeling the beam after it exits the nozzle. 
 
To act as a pilot study, this work focuses on developing and applying method 
(B), establishing a beam model for the Maryland Proton Treatment Center facility in 
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Baltimore, MD using their reference beam data used in commissioning of their treatment 
planning system (TPS). In future studies, this will be applied to multiple proton therapy 
treatment centers, from each facility using patient-specific treatment DICOM without 
requiring blueprints from the facility or extra measurements. 
 
2.4.2 Active scanning proton therapy dose reconstruction modules 
To reconstruct dose for epidemiologic studies of proton therapy treatments from 
multiple institutions, it is first required to establish a Monte Carlo model of each 
treatment facility and then recreate the treatments at those facilities using the facility-
specific models in combination with patient-specific treatment data. This work 
establishes a generic method to recreate facility- and patient-specific proton therapy 
treatments and acquire organ dose for each patient. The method is based on those 
described by Grevillot, et al. [98] and Grassberger, et al. [99] by using reference 
measurements typically available at each treatment facility.  
These described methods were implemented using Python modules to process 
input patient DICOM data, combined with parametric functions created from reference 
measurements. Modules then create input parameter files, and additional modules post-
process the TOPAS output to provide organ-specific dose and statistical information. 
The whole process is shown in Figure 19.  
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Figure 19. Flow chart demonstrating the proton treatment simulation method using 
patient treatment plans and typically-available reference measurements. 
 
2.4.3 Facility specific modules 
Simulations of facility-specific active scanning treatment plans require modeling 
the dose delivered to the patients using many individual “pencil beams” based on 
measurements from those facilities. A proton therapy treatment can have anywhere from 
tens to thousands of individual proton beams delivering dose in small dose “pockets” 
typically described as “spots” [99]. To create Monte Carlo simulations using only 
reference measurements, requires matching the beam output from the simulation to that 
of a specific facility. This includes matching the optical and energy distribution 
properties, along with calculating the number of protons necessary to deliver the 
prescribed dose. This is done using easily-available reference measurement data from 
the proton treatment facility obtained during the commissioning or part of routine quality 
assurance/quality control. 
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Creating these functions characterizing the proton beam for a single facility is an 
extensive and a time-consuming pursuit. However, this is a necessary procedure to 
establish accurate dosimetric treatment models to utilize in large-scale studies of proton 
therapy. To assess the dose received by the patients at each facility, each patient 
treatment plan is converted to Monte Carlo input parameter files. The treatment plans 
prescribe the necessary beam energy, beam size at the nozzle exit, and the position of 
each “spot”. Each individual beam is characterized by its energy distribution and optical 
properties. In this work a method is established to recreate facility-specific proton 
therapy treatments using the Monte Carlo simulation package, TOPAS [70] and is 
applied to the data from the Maryland Proton Treatment Center. 
 
2.4.4 Range and energy distribution matching 
Measurements commonly found at facilities include integral depth dose (IDD) 
curves in water phantoms. These curves are measured for specific energy ranges. The 
same energy values are then simulated in the TOPAS Monte Carlo code recreating each 
depth dose curve in order to match the ranges. The range, R90, is defined as the position 
of the 90% maximum of the curve in the Bragg peak distal fall-off along the beam path. 
The energy spectrum is considered to be Gaussian with a mean nominal energy, +,, and 
standard deviation, -..  
Functions are created to match the simulated energy and distribution at the beam 
nozzle exit to that of the treatment facility. This tuning is done by first, simulating the 
proton beam with the energy matching the prescribed energy and comparing the 
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simulations’ dose deposition with that from measurement. Then, the simulated energy is 
iteratively adjusted until the peaks of the curves from the measurement and simulation 
match. From the difference between the energies necessary to match the peaks, a 
function is created to adjust the TPS-prescribed energy for each beam.  
Then, the same is done with the energy distribution. To compare the two, the 
depth dose is first normalized by the area under the curve calculated between depths 0 
cm and the corresponding R90 for each energy. The energy distribution, -., is 
incrementally and iteratively adjusted. After each adjustment, the simulation is rerun, 
and the depth dose curve is checked to make sure that the curve matching is improving. 
After the best-matched sigma is found for each measured energy, a function is also 
created to estimate the most appropriate -. for each nominal energy, +,, approximating 
it with the polynomial [98], 
 -.(+,) = 	234 ∗ +,456  (12) 
with 34 being the polynomial coefficients and +,4  the nominal energy. 
 
2.4.5 Modeling beam optics  
Modules are also created to calculate the optical properties of the proton beam. 
These are described by the beam size, -7("), beam divergence, -849,7("), and the beam 
emittance :7(") along the beam path, defined as +z. These modules are based on the 
nominal energy, +, to calculate the beam divergence. To match the optical properties of 
the TOPAS simulation with that of the treatment facility, reference beam size 
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measurements around the isocenter are typically available for the same energies as those 
used to match the dose for the IDDs. 
At any position along the beam path (defined as the +" axis), the probability 
density functions of protons in the x-and y-planes follow normal distributions. At a 
position, ", the beam size is defined as -< in the x-axis, -= in the y-axis, following the 
Gaussian function, 
 >?@(A, ") = 6BC√EF GHIJK CLCMJ	  (13) 
where -7 is the standard deviation of the Gaussian in the x- or y- axes and A is the lateral 
distance from the isocenter in the x- or y- directions. 
The beam divergence, or angular spread distribution, describes the change in spot 
size with distance along the beam path. To match the beam divergence, in-air reference 
measurements are taken around the isocenter. Although, due to the intrinsic properties, 
the beam size should be smallest at the isocenter, the spot sizes actually keep increasing 
away from the nozzle exit because the beam is also diverging due to scatter in air as is 
shown in Figure 20. 
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Figure 20. Illustrative display of spot size properties of the proton beam with the 
isocenter at Z position, 0 mm. 
 
To calculate the intrinsic beam divergence at the nozzle exit, reference spot size 
measurements are taken at several positions around the isocenter, and Monte Carlo 
simulations with no divergence are created to account for air scatter. The slope of the 
change in measured spot sizes corresponds to the combined beam divergence from air 
and intrinsic properties [98], and the measured divergence, -849,NOPQ7RO8	 , is assumed to 
be due to the combined effects defined as, 
 -849,SOPNE + -849,P4RE = 	-849,NOPQ7RO8E  (14) 
where -849,SOPN	  is the intrinsic beam divergence (in the x- and y- direction), and -849,P4R	 	is the beam divergence due to air scatter.  
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To derive, -849,NOPQ7RO8	 , measurements around the isocenter are fit to the 
Gaussian function to acquire spot sizes, -< and -=. Beam divergences are then calculated 
from the slope of the change in spot size [98] and the divergence properties of the beam 
are defined independently as -849,< and,	-849,=. To derive -849,P4R , Monte Carlo 
simulation are created with an intrinsic beam divergence set to 0, and the change in 
beam size is assumed to be solely due to interactions in air.  
The spatial and angular beam spread distributions are Gaussian [98] and 
correlated. This correlation is described by the emittance parameter responsible for the 
rotation of the phase space. As the beam at the nozzle exit was considered purely 
divergent, the beam emittance is set empirically [98],  
 :7 = 0.5 ∗ 	-7 ∗ π	 (15) 
where :7 is the beam emittance at the beam nozzle exit (in both the x and y-direction) 
that is calculated from the x- and y-spot sizes, -7, at the beam nozzle exit. 
After the intrinsic beam properties are calculated, facility-specific Python 
modules are established. These modules estimate the beam divergence at the nozzle exit 
based on the nominal energy +,. The beam divergence in the x-direction, -849,< and in 
the y-direction, -849,=, are estimated by third-order polynomial approximation functions, 
 -849,<(+,) = 	234 ∗ +,456  (16) 
and, -849,=(+,) = 	2X4 ∗ +,456  (17) 
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2.4.6 Absolute dose matching 
To describe the number of protons used to deliver the dose to the defined region, 
each individual delivered “spot” has an associated Monitoring Unit (MU), which is 
logged in the DICOM treatment plan. To simulate a treatment, it is therefore necessary 
to convert the number of prescribed MUs based on the measurements from a treatment 
facility. To do this type of absolute dose matching, there are different approaches that 
can be used based on the available data. For example, simulations can be compared to 
Faraday cup measurements of the number of protons that exited the nozzle [100], 
performing absolute dosimetry using a calorimeter [101], or using an ionization chamber 
for the reference dosimetry [102]. From these dosimetry techniques, only absolute 
dosimetry with a Faraday cup (FC) and reference dosimetry with an ionization chamber 
(IC) have been found suitable for routine clinical use and are considered to achieve good 
agreement between each other [103, 104].  
Unfortunately, due to time constraints, for this work, neither measurement dose 
validation nor the recommended dose matching method was used. Instead, it was 
assumed that the treatment planning system was commissioned to deliver accurate dose 
to the prescribed region. The simulated physical dose due to protons was then used to 
normalize to the treatment planning prescribed dose. In this work, the dose is therefore 
reported as mGy or mSv per Gy received by the prescribed region as was simulated using 
TOPAS MC. 
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2.4.7 Patient-specific (TPS) parameters 
 Scripts were also written in Python to read and analyze the patient-specific 
DICOM data log files. These files consist of header information and CT image, position 
of organ structures that were contoured during treatment planning, and the ion beam plan 
prepared by the treatment planning system optimized to avoid organs at risk. The data 
about the patient and treatment setup is used to create inputs that are compatible with 
TOPAS input parameter files. In addition, Python modules were created based on the 
beam characterization methods described in the previous sections. These modules read 
the DICOM ION treatment plan and convert the prescribed beam parameters, modifying 
values based on the facility-specific conversion functions for Monte Carlo simulations. 
This method was kept as general as possible, requiring only facility-specific conversion 
functions to be changed to create the facility-specific parameter files.  
 
2.4.8 Modeling the Maryland Proton Treatment Center proton beam 
For this work, beam characterization modules were created from beam data 
library (BDL) measurements made by medical physicists at the Maryland Proton 
Treatment Center (MPTC) in Baltimore, MD. The integral depth dose (IDD) profiles and 
spot measurements were performed for 19 energies ranging from 70 MeV to 245 MeV 
as is shown in Figure 21. The IDD measurements had a range accuracy estimated to be 
within 0.5 mm and the measured dose fluctuations within 1%. The same 19 energies are 
simulated in TOPAS using a 10 cm by 10 cm field, with dose scored along the beam 
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path in a water phantom created from the GEANT4-preferred material for water, 
G4_WATER.  
To match the energy range, the simulation energy distribution was set to 0. After 
the simulation, the measured and simulated depth dose deposition curves are compared 
by evaluating peak-to-peak distances. The energy was incrementally changed until the 
difference was as close to 0 as possible. The physical range in the water phantom, R90, 
was then calculated for each Bragg peak as the distal 90% dose point for the 19 
simulated and measured energies. For each matched energy range, the best energy 
spread was determined empirically by simulating different energy distributions around 
the estimated values. The best energy spread was again determined visually by 
evaluating and minimizing the point-to-point dose differences.  
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Figure 21. Measured integral of depth doses (IDDs) curves generated from 19 beam 
energies from the Maryland Proton Treatment Center. The first curve represents 
dose from the 70MeV beam and the last curve represents the 245 MeV beam.†  
 
At the Maryland Proton Treatment Center, spot size measurements in the x- and 
y-lateral directions were taken at the isocenter, and several locations around it (at -20 
cm, -10 cm, 0 cm, 10 cm, 20 cm from the isocenter). As is typically found at treatment 
facilities, these measurements are for the same energies as those used for range and 
distribution matching. The 2D distributions of spot size measurements at the isocenter 
                                               
† Measurements obtained from Dr. Ulrich Langner at the Maryland Proton Treatment Center in Baltimore, 
MD. 
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are shown for all 19 beam energies in Figure 22 (A) and simulations of the spot sizes 
around the isocenter are shown in Figure 22 (B). The measurements and simulations are 
fitted automatically with an independent Gaussian function in each axis to accurately 
and reproducibly extract the spot sizes in the x- and y- directions.  
 
Figure 22. Measured‡ and simulated spot sizes based on MPTC data with A) 
showing the measurements taken at isocenter and B.1) and B.2) showing the 2D 
profiles of the simulated spots at +10 cm and -10 cm from the isocenter. 
                                               
‡	Measurements	obtained	from	Dr.	Ulrich	Langner	at	the	Maryland	Proton	Treatment	Center	in	Baltimore,	MD.	
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2.4.9 Patient specific (TPS) input data 
TOPAS has the capability of reading DICOM CT image data and implement it 
directly into the Monte Carlo code to model patient anatomy [70]. This work focuses on 
converting the patient-specific treatment plans to simulate the proton beam used to 
irradiate the patient. DICOM ION plan files describe the treatment plan using one or 
multiple fields, with each field being described by a gantry angle and a collection of 
pencil beams. Each pencil beam is then characterized by its weight (MU), position in the 
isocenter plan, and its energy at the nozzle entrance. The Patient Specific module reads 
the DICOM ION plan description files converting that data to TOPAS input parameter 
files using the parameterized functions established from reference measurement data 
described in the previous sections.  
 
2.4.10 Output-processing module 
The TOPAS simulation code is relatively new and there have been some 
obstacles in its implementation. Several features of interest in previous TOPAS versions 
had issues or would increase computation time, therefore it was necessary to create post-
processing modules to fill in those gaps. For example, to carry out organ dose 
calculation, it was necessary to create a post-processing module in Python. To do so, the 
pydicom Python library was used to import the patient DICOM CT image, DICOM RS 
structure set, and the output dose from TOPAS which in the DICOM RD format, which 
has the dose on the same grid as the DICOM CT. Using the DICOM RS data, a 3D 
binary mask is created for each organ structure. As each binary mask is of the same size 
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as the DICOM CT image and the dose grid, the two are overlaid to produce the organ-
based dose, allowing for easy calculation of the organ mean dose. This is done for each 
particle-type, for both the dose and standard deviation. The dose during the TOPAS 
simulations is recorded on the same dose matrix as the DICOM CT image, split by 
particle type (proton, electron, neutron, and gammas) with the neutron dose split into 
energy bins and saved as separate dose files. For this study, to account for RBE, the dose 
from protons was corrected by a factor of 1.1 irrespective of energy [51] as is done by 
the treatment planning software. However, for more accurate calculation and further 
investigation of treatment planning software inaccuracies, an LET-corrected dose can be 
scored to take into account the varying RBE along the proton beam path.  
Previously, ICRP 60 recommended a step function to parameterize energy-
dependent neutron quality factors. More recently, ICRP 103 mad a change in this 
recommendation moving to a continuous energy dependence [105]. In this work, 
however, the neutron dose was scored by energy bins of 0 to 10 keV, 10 keV to 100 
keV, 100 keV to 2 MeV, 2 MeV to 20 MeV, 20 MeV and above, to fit the previous 
(ICRP 60) radiation weighting factor model. However, the input parameter and output 
processing code can also be easily extended to have TOPAS score the neutron dose split 
by finer resolution energy bins to comply with the ICRP 103 continuous radiation 
weighting factors instead. 
Using the organ-based dose, it is now possible to do further calculations. In the 
following section, risk calculations were completed for specific proton treatment 
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simulations using pediatric phantoms and realistic treatment plans, by applying post-
processing risk calculation modules. 
 
2.5 Applying beam model to calculate organ dose and calculate risk 
ICRP reference computational phantoms of ages one and five [78] were sent to a 
certified medical physicist at the University of Maryland to add a common treatment 
plan. Medulloblastoma was chosen because it is one of the most common pediatric 
tumors of the central nervous system [106] and are commonly treated at MPTC. The 
phantoms are in DICOM CT image and DICOM RS structure format and were used to 
plan a treatment for a medulloblastoma-type tumor (Figure 23). Then, following the 
methods established in the previous sections, Monte Carlo simulations were run to 
determine the patient-specific, in- and out-of-field doses. 
 
 
Figure 23. A) One- and B) Five- year old phantoms with a medulloblastoma-type 
treatment. 
 
The dose to each voxel was scored during the TOPAS Monte Carlo simulations 
as a function of particle type. The output-processing modules were used to calculate 
A) B)
 71 
 
organ dose, taking into account the radiation weighting factors of all primary and 
secondary particles [107].  
Modules were created in Python to use the patient equivalent organ dose 
calculated from the TOPAS Monte Carlo simulation of a proton therapy treatment, and 
implement the Biological Effects of Ionizing Radiation (BEIR) VII risk models [10], 
described in previous chapters. The modules calculate the BEIR VII Excess Relative 
Risk (ERR), Excess Absolute Risk (EAR), and the Lifetime Attributable Risks (LAR) 
for solid cancers of several organs. These models were applied to the doses received by 
the pediatric phantoms undergoing brain treatment simulations as described in the 
previous section. 
The LAR is summed over an assumed age of 100 years of solid cancer incidence 
for the phantoms. On the recommendation of the BEIR VII report [10] the ERR is scaled 
on a log scale by a weight of 0.7 and the absolute risk is given a weight of 0.3. Of the 
large set of organs for which dose is calculated for each treatment, risk calculations of 
solid cancer incidence are only calculated for stomach, colon, liver, lung, and bladder 
cancers because of a lack of data and risk models for the other organs. Unexposed 
lifetime baseline risks based on Kocher et al. [25] and analyses of cancer incidence were 
based on cases diagnosed in the period 1958-1998 [108]. 
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3 RESULTS 
3.1 ANATOMY EXTENSIONS 
For comparison purposes the mean organ doses for the chest and prostate cases 
were compared relative to that calculated for the heart and prostate, respectively. The 
resulting percent organ doses for the chest and the prostate irradiation cases are tabulated 
in percent dose differences for the reference and APE phantoms compared to the patient 
CAP CT are shown in Table 2 and 3 and are depicted in Figure 24. 
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Table 2. Examples of percent dose (%) in radiotherapy chest irradiations for the reference phantom, APE phantoms, 
and full CAP CT patient anatomies. The organs completely included in the partial-body CT images used to construct 
the APE are marked in bold.  
 
 
Organ 
Ref. 
Patient 1 
APE Patient Ref. 
Patient 2 
APE Patient Ref. 
Patient 3 
APE Patient 
Heart 88.569 100.14 100 88.569 100.14 100 88.569 100.14 100 
Lung Left 
22.845 28.774 28.714 22.845 28.774 28.714 22.845 28.774 28.714 
Lung Right 
22.274 19.725 19.711 22.274 19.725 19.711 22.274 19.725 19.711 
Liver 4.268 11.653 12.504 4.268 11.653 12.504 4.268 11.653 12.504 
Stomach 3.925 9.203 9.169 3.925 9.203 9.169 3.925 9.203 9.169 
Bladder 
0.032 0.032 0.045 0.032 0.032 0.045 0.032 0.032 0.045 
Prostate 
0.016 0.016 0.029 0.016 0.016 0.029 0.016 0.016 0.029 
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Table 3. Examples of percent dose (%) in radiotherapy prostate irradiations for the reference phantom, APE 
phantoms, and full CAP CT patient anatomies. The organs completely included in the partial-body CT images used to 
construct the APE are marked in bold. 
 
Organ 
Ref. 
Patient 1 
APE Patient Ref. 
Patient 2 
APE Patient Ref. 
Patient 3 
APE Patient 
Prostate 99.505 100.81 100 100.055 99.999 100 99.064 100.041 100 
Bladder 45.877 87.911 87.898 46.13 65.529 65.516 45.674 95.419 95.439 
Stomach 0.063 0.072 0.089 0.063 0.066 0.056 0.063 0.136 0.128 
Liver 0.054 0.074 0.086 0.054 0.071 0.07 0.054 0.123 0.117 
Heart 0.016 0.019 0.034 0.016 0.023 0.017 0.016 0.032 0.028 
Lung	Right 0.011 0.017 0.034 0.012 0.016 0.019 0.011 0.022 0.027 
Lung	Left 0.011 0.018 0.026 0.011 0.016 0.018 0.011 0.021 0.026 
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Figure 24. Absolute percent difference (%) for the reference and APE phantoms 
compared to that calculated using the full CAP CT scans averaged over the five 
patients for the (a) chest and (b) prostate irradiation cases. The organs located in-
scan and out-of-scan. 
 
These results show that the APE phantoms offer some dosimetric advantages 
compared to using reference phantoms. As expected, the APE phantoms and CAP CT 
images resulted in nearly identical dosimetry for those organs which are fully included in 
the partial-body CT used to construct the APE (e.g., heart and lungs for the chest 
irradiation case, and prostate and bladder for the prostate irradiation case). The reference 
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phantoms showed, on average, organ dose differences of up to 20% and 52% in the chest 
and prostate cases, respectively, compared to that calculated using the full CAP scan 
images. The improved accuracy in the dosimetry for the APE phantoms clearly 
demonstrates the benefit of using patient-specific anatomy. 
The results for the out-of-scan organ dosimetry were mixed. In many cases the 
organ doses were improved compared to the reference phantom (e.g., difference of 57% 
for the reference phantom vs. 0.4% APE phantom for the stomach in patient 1 chest 
case). In other cases, however, there was no significant difference observed and 
sometimes the reference phantom showed better agreement (e.g. 6% reference phantom 
vs. 35% APE phantom for the heart in patient 2 abdomen case). Overall, however, the 
results still show that the APE phantoms perform similarly or better than the reference 
phantom. For the chest irradiation case, the average absolute difference for the out-of-
scan organs was reduced from 31% (reference phantom) to 26% (APE phantom). For the 
prostate irradiation case, the average difference decreased from 41% (reference 
phantom) to 17% (APE phantom). 
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3.2 SCATTER COMPARISON 
There was good agreement between MCNP6 and TOPAS simulations for 
scattering neutrons. However, there were significant discrepancies between the 
experimental setup and the simulations, which are not explained by sensitivity analysis. 
As an example, Figure 25 shows the physical bubbles produced by neutron interaction 
with the detector gel. The unfolded neutron energy spectrum from the bubble detectors 
results in large error bars, which don’t overlap with the simulation results. The MCNP is 
a well-validated code [83, 84, 92, 109-113], and an AAPM Task Group 152, which was 
released after this work was completed, recommend the use of already established Monte 
Carlo simulation codes as the basis of out-of-field secondary neutron scatter validation 
studies [114].  
 
 
Figure 25. Photo of bubbles in detectors following irradiation by Cf-252. 
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A comparison of simulated and measured neutron spectra by TOPAS, MCNP, 
and Bubble Detectors in shown in Figure 26. 
 
 
Figure 26. Comparison of simulated and measured spectrum by TOPAS, MCNP4, 
and Bubble Detectors.  
 
Further simulations were run using TOPAS to attempt to account for the 
discrepancies between theoretical and the unfolded response of bubble detectors; 
however, these simulations did not yield any significant differences, resulting in the 
                                               
4 MCNP simulations were carried out by Dr. Matthew Mille at the National Cancer Institute in Rockville, 
MD. 
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conclusion that the bubble detectors’ sensitivity was not high enough to accommodate 
for such radiation levels. Therefore, it was determined that the best way to benchmark 
neutron scatter simulated by TOPAS is through comparisons with MCNP and evaluating 
neutron fluence using a finer resolution. The results are reported in Figure 27.  
 
 
Figure 27. Comparison of simulated neutron spectrum by TOPAS and MCNP5 in 
bins with finer resolution. 
 
The fact that the simulations were well-matched leads to the conclusion that the 
bubble detectors were not be appropriate for experimental verification using this method, 
and that utilizing TOPAS simulations will result in comparable neutron fluence as that 
from the well-validate MCNP for the simulated regions. 
                                               
5 MCNP simulations were carried out by Dr. Matthew Mille at the National Cancer Institute in Rockville, 
MD. 
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3.3 PROTON BEAM MODELING 
First, the simulated energy range and energy spread were matched with that 
measured at the Maryland Proton Treatment Center. To do so, the energy and energy 
spread were adjusted iteratively until the best match was achieved via visual inspection 
of the beam range and dose distribution, several of the curves are shown in Figure 28.  
 
 
Figure 28. Sample of four (70, 80, 90, and 100 MeV) of the 19 depth-dose profiles of 
comparing measured dose deposition6 and dose simulated by TOPAS. 
 
                                               
6 Measurements obtained from Dr. Ulrich Langner at the Maryland Proton Treatment Center in Baltimore, 
MD. 
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Figure 29 shows the calculated range correction linear fit calculated from the 
measurement and simulations. 
 
Figure 29. Correcting for range differences by accounting for the energy difference 
between the beam nozzle entrance and the beam nozzle exit.  
 
Once the simulations appropriately matched the measurement data for each of the 
19 energies, energy standard deviation based on the prescribed nominal energy, !"  from 
the third-order polynomial function as is shown in Figure 30. These functions are part of 
the MPTC facility-specific module that create TOPAS input parameters of the beam 
energy distribution.  
 
 82 
 
 
Figure 30. Energy distribution curve create based on the Maryland Proton 
Treatment Center. 
 
3.3.1 Organ dose calculations 
Using the Monte Carlo code TOPAS, proton treatments based on measurement 
data from the Maryland Proton Treatment Center were simulated using a one-year-old 
and a five-year-old computational phantom.  
From this simulation study, it was noted that the majority of out-of-field dose is 
from secondary neutrons, as expected. Recent studies of neutron dose have shown organ 
equivalent doses decrease rapidly with increasing distance from the treatment volume 
[51]. Equivalent doses were analyzed for the phantoms and dose to organs for which 
structure contours were available were scored. To do so, dose from all particles, such as 
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neutron dose was scored per voxel in all possible organs and the equivalent organ dose 
was combined per organ first as in Table 4 and Table 5, before combining them into 
dose using the ICRP radiation weighting factors, shown in Table 5 and Table 6. 
  
Table 4. Equivalent neutron dose (mSv/Gy) for the one-year-old phantom scored 
based on the energy step function matching the ICRP 60 weighting factors 
Organ 
0-10	keV	
(mSv/Gy)	
10	keV	–	100	keV	
(mSv/Gy)	
100	keV	–	2	MeV	
(mSv/Gy)	
2	MeV	–	20	MeV	
(mSv/Gy)	
Above	20	
MeV	
(mSv/Gy)	
Adrenal Gland 0.00E+00 0.00E+00 0.00E+00 7.99E-05 4.18E-06 
Bladder 0.00E+00 0.00E+00 0.00E+00 0.00E+00 1.90E-04 
Brain 3.86E-05 5.25E-05 1.22E-04 1.23E-04 1.21E-04 
Breast (adipose) 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
Bronchus 0.00E+00 0.00E+00 3.09E-05 1.05E-04 2.33E-04 
Colon 0.00E+00 2.58E-06 3.03E-05 1.03E-04 1.23E-04 
Ear (external) 0.00E+00 6.36E-05 1.38E-04 1.32E-04 7.62E-05 
Esophagus 0.00E+00 1.33E-06 1.27E-04 8.71E-05 2.03E-04 
Eyes 2.80E-08 2.53E-05 1.73E-04 1.35E-04 1.08E-04 
Gallbladder 0.00E+00 0.00E+00 2.47E-05 1.13E-04 9.48E-06 
Heart 0.00E+00 1.49E-05 7.98E-05 1.04E-04 1.18E-04 
Kidney 0.00E+00 0.00E+00 4.40E-05 1.14E-04 6.25E-05 
Larynx 0.00E+00 5.91E-08 9.40E-05 1.05E-04 1.05E-04 
Lens 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
Liver 0.00E+00 0.00E+00 1.02E-04 1.04E-04 1.25E-04 
Lung 8.01E-06 1.09E-08 1.80E-04 2.29E-04 2.36E-04 
Nose 0.00E+00 0.00E+00 1.52E-04 7.95E-05 1.65E-04 
Pancreas 0.00E+00 0.00E+00 4.63E-06 5.54E-05 9.40E-05 
Parotids 6.73E-08 5.85E-05 1.19E-04 1.18E-04 1.05E-04 
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Table 4. (Cont.)  
Organ 
0-10	keV	
(mSv/Gy)	
10	keV	–	100	keV	
(mSv/Gy)	
100	keV	–	2	
MeV	(mSv/Gy)	
2	MeV	–	20	MeV	
(mSv/Gy)	
Above	20	
MeV	
(mSv/Gy)	
Penis 0.00E+00 0.00E+00 0.00E+00 0.00E+00 4.51E-05 
Pituitary 0.00E+00 5.56E-05 5.14E-05 1.13E-04 6.86E-05 
Prostate 0.00E+00 0.00E+00 0.00E+00 1.31E-04 0.00E+00 
Scrotum 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
Skin 3.59E-05 4.68E-05 1.17E-04 1.19E-04 1.20E-04 
Spleen 0.00E+00 0.00E+00 1.19E-04 1.24E-04 6.94E-05 
Stomach 0.00E+00 5.40E-09 5.67E-05 1.04E-04 7.43E-05 
Subl gland 0.00E+00 3.89E-07 7.31E-05 1.15E-04 1.36E-04 
Submand gland 0.00E+00 5.06E-06 9.52E-05 1.13E-04 8.39E-05 
Thymus 0.00E+00 1.24E-07 9.18E-05 1.07E-04 1.20E-04 
Thyroid 0.00E+00 0.00E+00 8.92E-05 1.14E-04 1.37E-04 
Tongue 5.60E-09 5.92E-06 9.21E-05 1.12E-04 1.53E-04 
Tonsil 0.00E+00 1.94E-06 1.12E-04 1.55E-04 6.13E-05 
Trachea 0.00E+00 0.00E+00 1.66E-05 9.26E-05 1.34E-04 
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Table 5. Neutron equivalent dose (mSy/Gy) for the five-year-old phantom scored 
based on the energy step function to match the ICRP 60 weighting factors 
Organ 0-10	keV	
(mSv/Gy) 
10	keV	–	100	keV	
(mSv/Gy) 
100	keV	–	2	MeV	
(mSv/Gy) 
2	MeV	–	20	MeV	
(mSv/Gy) 
Above	20	
MeV	
(mSv/Gy) 
Adrenal Gland 0.00E+00 0.00E+00 2.67E-05 1.51E-04 5.84E-05 
Bladder 0.00E+00 0.00E+00 0.00E+00 2.70E-04 3.71E-05 
Brain 4.72E-05 8.47E-05 1.83E-04 2.06E-04 1.75E-04 
Breast (adipose) 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
Bronchus 0.00E+00 0.00E+00 2.23E-04 1.78E-04 1.50E-04 
Colon 0.00E+00 0.00E+00 6.98E-06 1.91E-04 1.74E-04 
Ear (external) 9.34E-09 4.98E-05 2.09E-04 1.93E-04 1.18E-04 
Esophagus 0.00E+00 0.00E+00 2.13E-04 1.74E-04 1.38E-04 
Eyes 0.00E+00 9.38E-05 1.61E-04 1.96E-04 1.81E-04 
Gallbladder 0.00E+00 0.00E+00 0.00E+00 1.28E-04 1.66E-04 
Heart 0.00E+00 5.28E-07 1.42E-04 1.66E-04 1.36E-04 
Kidney 0.00E+00 0.00E+00 8.85E-05 1.92E-04 1.17E-04 
Larynx 5.46E-09 2.13E-04 1.07E-04 1.69E-04 2.00E-04 
Lens 0.00E+00 0.00E+00 1.99E-04 1.32E-05 2.97E-04 
Liver 0.00E+00 2.19E-05 1.33E-04 1.68E-04 1.70E-04 
Lung 0.00E+00 4.23E-05 3.07E-04 3.66E-04 3.13E-04 
Nose 0.00E+00 0.00E+00 6.54E-05 1.27E-04 4.08E-05 
Pancreas 0.00E+00 0.00E+00 0.00E+00 1.57E-04 1.56E-04 
Parotids 5.46E-09 7.05E-05 1.50E-04 1.82E-04 1.81E-04 
Penis 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
Pituitary 0.00E+00 0.00E+00 5.38E-05 2.30E-04 5.56E-05 
Prostate 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
Scrotum 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
Skin 4.42E-05 7.80E-05 1.75E-04 1.96E-04 1.74E-04 
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Table 5. (Cont.)  
Organ 
0-10	keV	
(mSv/Gy)	
10	keV	–	100	keV	
(mSv/Gy)	
100	keV	–	2	MeV	
(mSv/Gy)	
2	MeV	–	20	MeV	
(mSv/Gy)	
Above	20	
MeV	
(mSv/Gy)	
Spleen 0.00E+00 8.42E-08 2.17E-04 1.68E-04 2.13E-04 
Stomach 0.00E+00 1.11E-08 1.56E-04 1.70E-04 2.09E-04 
Subl	gland 0.00E+00 0.00E+00 1.22E-04 1.90E-04 1.31E-04 
Submand	gland 2.02E-07 4.44E-05 1.69E-04 1.75E-04 1.75E-04 
Thymus 0.00E+00 1.26E-06 1.85E-04 1.80E-04 1.59E-04 
Thyroid 0.00E+00 0.00E+00 1.14E-04 1.73E-04 1.69E-04 
Tongue 1.07E-04 8.97E-05 1.38E-04 1.73E-04 1.35E-04 
Tonsil 0.00E+00 2.02E-04 1.34E-04 1.79E-04 1.91E-04 
Trachea 0.00E+00 0.00E+00 9.21E-05 1.99E-04 1.79E-04 
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Table 6. TOPAS organ dose calculated of the medulloblastoma 3 field scanning beam proton treatment for the 1-year-
old-phantom 
Organ Total Dose 
(mSv/Gy) 
Neutron Dose* 
(mSv/Gy) 
Dose P 
(mSv/Gy) 
SD P 
(mSv/Gy) 
Dose E 
(mSv/Gy) 
SD E 
(mSv/Gy) 
Dose G 
(mSv/Gy) 
SD G 
(mSv/Gy) 
Adrenal Gland 8.20E-04 8.20E-04 0.00E+00 1.42E-08 0.00E+00 7.95E-09 1.44E-07 1.94E-11 
Bladder 9.50E-04 9.50E-04 0.00E+00 2.55E-08 0.00E+00 8.23E-09 9.30E-08 1.92E-11 
Brain 1.82E+02 5.00E-03 1.76E+02 6.27E-05 6.04E+00 1.38E-06 1.43E-05 1.33E-10 
Breast (adipose) 0.00E+00 0.00E+00 0.00E+00 4.44E-08 0.00E+00 1.00E-08 0.00E+00 0.00E+00 
Bronchus 4.26E-03 2.84E-03 0.00E+00 7.28E-08 1.42E-03 1.38E-08 1.39E-07 1.80E-11 
Colon 2.28E-03 2.28E-03 0.00E+00 1.45E-07 0.00E+00 8.10E-09 1.69E-07 2.11E-11 
Ear (external) 1.25E-01 5.09E-03 1.14E-01 3.22E-07 5.80E-03 2.39E-08 8.16E-07 6.68E-11 
Esophagus 4.44E-03 4.43E-03 0.00E+00 7.37E-08 0.00E+00 8.61E-09 2.46E-07 2.21E-11 
Eyes 5.61E-03 5.61E-03 0.00E+00 9.44E-08 0.00E+00 8.31E-09 2.03E-07 2.34E-11 
Gallbladder 1.67E-03 1.67E-03 0.00E+00 6.33E-08 0.00E+00 8.01E-09 1.20E-07 2.54E-11 
Heart 3.38E-03 3.38E-03 0.00E+00 8.69E-08 0.00E+00 8.13E-09 1.80E-07 2.45E-11 
Kidney 2.33E-03 2.33E-03 0.00E+00 9.22E-08 0.00E+00 8.21E-09 1.62E-07 2.05E-11 
Larynx 5.35E-03 3.46E-03 0.00E+00 9.48E-08 1.89E-03 1.05E-08 1.88E-07 2.24E-11 
Lens 9.42E-08 0.00E+00 0.00E+00 4.93E-09 0.00E+00 5.92E-09 9.42E-08 1.23E-11 
Liver 3.69E-03 3.69E-03 0.00E+00 9.01E-08 0.00E+00 8.01E-09 1.63E-07 2.16E-11 
Lung 7.58E-03 7.10E-03 0.00E+00 1.36E-07 4.72E-04 9.05E-09 3.44E-07 3.51E-11 
*Neutron dose is the organ dose weighted based on the ICRP 60 radiation weighting factors with the neutron dose data. 
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Table 6. (Cont.)  
Organ Total Dose 
(mSv/Gy) 
Neutron Dose* 
(mSv/Gy) 
Dose P 
(mSv/Gy) 
SD P 
(mSv/Gy) 
Dose E 
(mSv/Gy) 
SD E 
(mSv/Gy) 
Dose G 
(mSv/Gy) 
SD G 
(mSv/Gy) 
Pancreas 1.12E-03 1.12E-03 0.00E+00 5.20E-08 0.00E+00 8.47E-09 1.09E-07 1.92E-11 
Parotids 3.72E-02 4.68E-03 3.06E-02 1.39E-07 1.89E-03 1.12E-08 2.38E-07 2.25E-11 
Penis 2.26E-04 2.26E-04 0.00E+00 4.93E-09 0.00E+00 1.11E-08 1.46E-07 1.58E-11 
Pituitary 5.55E+01 3.06E-03 5.55E+01 8.88E-05 2.28E-02 1.08E-07 5.16E-07 3.07E-11 
Prostate 1.31E-03 1.31E-03 0.00E+00 0.00E+00 0.00E+00 1.37E-09 0.00E+00 0.00E+00 
Scrotum 1.22E-07 0.00E+00 0.00E+00 1.38E-07 0.00E+00 8.92E-09 1.22E-07 1.42E-11 
Skin 1.50E+02 4.78E-03 1.45E+02 4.20E-05 5.58E+00 7.24E-07 1.43E-05 1.28E-10 
Spleen 3.97E-03 3.97E-03 0.00E+00 1.15E-07 0.00E+00 8.01E-09 1.33E-07 1.96E-11 
Stomach 2.55E-03 2.55E-03 0.00E+00 1.13E-07 0.00E+00 7.93E-09 1.52E-07 2.06E-11 
Sublingual gland 3.30E-03 3.30E-03 0.00E+00 1.01E-07 0.00E+00 8.62E-09 2.23E-07 2.09E-11 
Submand. gland 4.45E-03 3.51E-03 0.00E+00 8.71E-08 9.43E-04 8.79E-09 1.76E-07 2.02E-11 
Thymus 3.51E-03 3.51E-03 0.00E+00 1.02E-07 0.00E+00 8.60E-09 1.77E-07 2.12E-11 
Thyroid 3.61E-03 3.60E-03 0.00E+00 8.45E-08 0.00E+00 8.86E-09 1.25E-07 1.72E-11 
Tongue 5.67E-03 3.78E-03 0.00E+00 9.54E-08 1.89E-03 9.63E-09 2.08E-07 2.31E-11 
Tonsil 5.07E-03 4.12E-03 0.00E+00 1.51E-07 9.47E-04 1.04E-08 1.45E-07 1.83E-11 
Trachea 1.93E-03 1.93E-03 0.00E+00 6.46E-08 0.00E+00 8.12E-09 1.66E-07 1.93E-11 
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Table 7. TOPAS organ dose calculated of the medulloblastoma 3 field scanning beam proton treatment for the five-
year-old treatment 
Organ Total Dose 
(mSv/Gy) 
Neutron Dose* 
(mSv/Gy) 
Dose P 
(mSv/Gy) 
SD P 
(mSv/Gy) 
Dose E 
(mSv/Gy) 
SD E 
(mSv/Gy) 
Dose G 
(mSv/Gy) 
SD G 
(mSv/Gy) 
Adrenal Gland 2.33E-03 2.33E-03 0.00E+00 7.65E-08 0.00E+00 6.49E-09 1.59E-07 5.11E-11 
Bladder 2.88E-03 2.88E-03 0.00E+00 9.49E-08 0.00E+00 6.60E-09 1.55E-07 2.04E-11 
Brain 2.59E+02 7.68E-03 2.52E+02 9.08E-05 6.92E+00 1.64E-06 1.70E-05 1.08E-10 
Breast (adipose) 7.07E-08 0.00E+00 0.00E+00 0.00E+00 0.00E+00 5.20E-09 7.07E-08 1.01E-11 
Bronchus 7.00E-03 7.00E-03 0.00E+00 8.32E-08 0.00E+00 7.12E-09 1.53E-07 1.71E-11 
Colon 2.92E-03 2.92E-03 0.00E+00 9.08E-08 0.00E+00 6.52E-09 1.47E-07 2.50E-11 
Ear (external) 2.77E+00 7.21E-03 2.62E+00 3.04E-06 1.48E-01 1.62E-07 1.48E-06 6.59E-11 
Esophagus 6.69E-03 6.69E-03 0.00E+00 6.14E-08 0.00E+00 7.76E-09 1.43E-07 2.47E-11 
Eyes 7.01E-03 7.01E-03 0.00E+00 8.01E-08 0.00E+00 7.40E-09 1.79E-07 2.41E-11 
Gallbladder 2.12E-03 2.12E-03 0.00E+00 8.71E-08 0.00E+00 6.79E-09 1.20E-07 1.19E-11 
Heart 5.19E-03 5.19E-03 0.00E+00 7.73E-08 0.00E+00 6.68E-09 1.45E-07 2.45E-11 
Kidney 4.27E-03 4.27E-03 0.00E+00 7.74E-08 0.00E+00 6.67E-09 1.47E-07 2.24E-11 
Larynx 1.02E-02 6.96E-03 0.00E+00 7.50E-08 3.24E-03 9.53E-09 1.64E-07 2.48E-11 
Lens 5.60E-03 5.60E-03 0.00E+00 6.17E-08 0.00E+00 8.29E-09 1.06E-07 2.36E-11 
Liver 5.41E-03 5.41E-03 0.00E+00 7.60E-08 0.00E+00 6.49E-09 1.46E-07 2.53E-11 
*Neutron dose is the organ dose weighted based on the ICRP 60 radiation weighting factors with the neutron dose data 
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Table 7.  (Cont.)  
Organ Total Dose 
(mSv/Gy) 
Neutron Dose* 
(mSv/Gy) 
Dose P 
(mSv/Gy) 
SD P 
(mSv/Gy) 
Dose E 
(mSv/Gy) 
SD E 
(mSv/Gy) 
Dose G 
(mSv/Gy) 
SD G 
(mSv/Gy) 
Lung 1.23E-02 1.18E-02 0.00E+00 1.05E-07 5.00E-04 7.75E-09 3.37E-07 4.86E-11 
Nose 3.83E-03 2.79E-03 0.00E+00 8.67E-08 1.05E-03 6.44E-09 2.93E-07 2.96E-11 
Pancreas 2.35E-03 2.35E-03 0.00E+00 8.40E-08 0.00E+00 6.52E-09 1.32E-07 2.22E-11 
Parotids 3.26E-02 6.43E-03 2.41E-02 8.28E-08 2.08E-03 1.08E-08 2.17E-07 2.58E-11 
Penis 9.66E-08 0.00E+00 0.00E+00 7.57E-09 0.00E+00 6.07E-09 9.66E-08 1.18E-11 
Pituitary 4.70E-03 3.66E-03 0.00E+00 7.49E-08 1.05E-03 1.27E-08 2.65E-07 2.68E-11 
Scrotum 0.00E+00 0.00E+00 0.00E+00 9.46E-08 0.00E+00 6.21E-09 0.00E+00 0.00E+00 
Skin 2.05E+02 7.33E-03 1.99E+02 5.19E-05 6.44E+00 7.38E-07 1.79E-05 1.02E-10 
Spleen 7.09E-03 7.09E-03 0.00E+00 8.78E-08 0.00E+00 6.63E-09 1.52E-07 2.48E-11 
Stomach 5.86E-03 5.86E-03 0.00E+00 7.87E-08 0.00E+00 6.59E-09 1.36E-07 2.18E-11 
Subl gland 4.99E-03 4.99E-03 0.00E+00 8.42E-08 0.00E+00 7.63E-09 1.78E-07 2.57E-11 
Submand gland 7.44E-03 6.44E-03 0.00E+00 8.25E-08 9.99E-04 9.50E-09 2.23E-07 2.90E-11 
Thymus 6.30E-03 6.30E-03 0.00E+00 7.73E-08 0.00E+00 7.09E-09 1.43E-07 2.77E-11 
Thyroid 4.86E-03 4.86E-03 0.00E+00 7.10E-08 0.00E+00 7.73E-09 1.38E-07 2.93E-11 
Tongue 8.64E-03 6.60E-03 0.00E+00 7.93E-08 2.05E-03 9.13E-09 2.10E-07 2.52E-11 
Tonsil 2.16E-02 7.44E-03 1.21E-02 9.32E-08 2.05E-03 1.23E-08 2.62E-07 2.47E-11 
Trachea 4.73E-03 4.73E-03 0.00E+00 8.54E-08 0.00E+00 7.27E-09 1.32E-07 3.32E-11 
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3.4 RISK CALCULATIONS OF SECONDARY CANCER INCIDENCE 
Excess Relative Risks (ERR), Excess Absolute Risks (EAR) and Lifetime 
Attributable (LAR) risks of cancer incidence due to the proton therapy were calculated 
for the one and five-year-old phantoms. While the data for cancer-incidence in general is 
numerous, data is limited for organ-specific cancer incidence limiting the risk analysis 
possible. As such, ERR’s was calculated for both cases for stomach, colon, liver, lung, 
and bladder. EAR’s was calculated for both cases for stomach, colon, liver, lung, bladder 
and prostate. ERR and EAR calculated for the one-year-old phantom are shown below. 
 
 
Figure 31. ERRs calculated for a scanning proton therapy medulloblastoma 
treatment of a 1-year-old phantom 
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Figure 32. EAR calculations for a proton therapy medulloblastoma treatment of a 
1-year-old phantom 
 
LAR’s were calculated for the one-year-old, and five-year-old phantoms for 
cancer tumor induction in the stomach, colon, liver, lung, and bladder shown in 
calculated by the BEIR VII risk models using the linear dose-response models, shown in 
Table 7 below. 
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Table 8. Table of Lifetime Attributable Risk of cancer incidence due do the proton 
therapy treatment of the one and five-year-old phantoms 
Organ 
One-year-old	
phantom	
LAR	(%) 
Five-year-old	
phantom	
LAR	(%) 
Stomach 0.00244 0.00339 
Colon 0.00623 0.00483 
Liver 0.00135 0.00119 
Lung 0.111 0.108 
Bladder 0.00371 0.00678 
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4 DISCUSSION  
4.1 OVERVIEW 
The goal of this dissertation was to investigate and develop methods that improve 
dose reconstruction in epidemiologic studies. This work will be utilized by 
epidemiologists for further investigation of the radiation dose-response model. It will 
also allow for dose reconstruction of patients undergoing proton therapy with potentially 
higher accuracy than that estimated by clinicians administering the dose. In addition, 
these methods can be used to calculate the risks from the low doses received using 
already established risk models. 
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4.2 ANATOMY EXTENSION 
The main objective of the anatomy extension section was to develop an improved 
method for dose reconstruction of patients undergoing radiotherapy using the limited 
available anatomical data. One important application is for epidemiologic studies aimed 
at assessing the risks of late-effects following both photon and proton radiotherapy. For 
example, at the National Cancer Institute it was found that the thyroid is consistently 
located just beyond the typical CT scan range used for breast radiotherapy planning. And 
while the majority of second primary tumors occur within the beam-bordering region, 
previous studies have found that about 20% are located in tissues 5 to 30 cm away from 
the irradiated volume [75]. Therefore, methods are needed to accurately estimate the 
dose deposited in these regions of epidemiologic interest. 
To account for the fact that this region is not of clinical interest and there is no 
anatomy representing organs and tissue in these regions, our anatomy extension 
algorithm helps aid in the assessment of dose simultaneous near and distant to the tissues 
of primary clinical interest. It is worthwhile to note that in this study, the organ doses 
were compared between a reference phantom and patient chest-abdominal-pelvic (CAP) 
CT scans and then between the APE phantoms and patient CAP CT scans. Organ doses 
between body size-matched phantoms and patient CAP CT scans were also compared. 
However, this latter comparison was not included in this dissertation because there was 
not an observably clear improvement compared to simply using reference phantoms. It 
was found that anatomical variability in different patients cannot be captured simply by 
changing the size of the phantoms, which underscores the importance of the APE 
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technique. This is done by capturing as much patient-specific anatomy as possible for 
improving the dosimetry. While not perfect, the APE method has some important 
advantages over previous dose reconstruction methods that do not consider patient-
specific anatomy at all [8, 13, 71].  
The author acknowledges the limitations of the APE method as follows. First, 
manual contouring of patient CT images is still required. However, the phantom CT 
images are already contoured and do not require further modification. It was presumed 
that key organs at risk are already segmented during radiotherapy planning and no 
further contouring would be required for this work. Atlas-based automatic segmentation 
methods are currently being explored for additional organs of interest in epidemiologic 
studies and it may be possible to incorporate this into this APE method. Second, the 
author has so far only demonstrated the APE using images extracted from CAP scans 
(i.e. from lung apices to symphysis pubis). The performance of the APE phantoms 
generated using other types of CT scans (e.g. Head and Neck CT scans) has not been 
tested, though it is believed the APE method is applicable to the entire body. Third, 
although the APE phantoms provide more accurate organ dose estimation than the 
reference phantom, the author acknowledges that a dose discrepancy between APE 
phantoms and patients still exists and methods are currently being investigated to resolve 
such issues.  
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4.3 TREATMENT SIMULATIONS 
4.3.1 TOPAS benchmarking 
The original goal was to use bubble detectors to benchmark neutrons scatter, due 
to their promising features of good spatial resolution and ability to provide a neutron 
energy spectrum. In this work, a comparison study of neutron scatter was created 
looking at neutron fluence due to a Cf-252 source and scatter through a phantom. 
However, to achieve good statistical power, it required a lengthy time of irradiation. One 
of the energy bins (above 10 MeV) only received one bubble detector after an irradiation 
of over 70 hours. Therefore, for this study it was more practical to use an already-
established Monte Carlo code, MCNP [92].  
In addition, an AAPM Task Group Report No. 158 Measurement and calculation 
of doses outside the treated volume from external-beam radiation therapy [114] was 
released after this work was completed. This task group report suggests methods of 
calculating neutron dose measurements at clinical facilities investigating neutron dose 
from their system. It recommends not using bubble detectors for neutron dose validation 
from proton therapy treatments.  
As such, while the measurements in this work were of neutrons in the range that 
were acceptable for use of bubble detectors, ultimately comparisons with MCNP were 
used. The two simulation codes compared well in the regions below 20 MeV. However, 
it will be beneficial to test the TOPAS code using a higher-energy source (above 20 
MeV). In addition, a higher dose rate or less shielding would be recommended for 
further comparison between TOPAS simulations and bubble detector measurements. 
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Additionally, further comparisons of scattered of neutron energies in the 20-275 MeV 
would also be recommended using other Monte Carlo codes. 
While this study used methods based on the TOPAS MC code, other methods 
should also be considered for epidemiologic studies. For example, there have been 
recent developments in analytical methods for neutron dose calculation for large-scale 
epidemiologic studies, such as the methods used by Zhang et al. [115] and Anferov, et al 
[116]. Dose comparisons between these analytical methods and Monte Carlo methods 
using TOPAS would be suggested for further investigations. Additionally, further 
studies can be created to investigate dose differences due to the uncertainties produced 
by the conversions of CT image (measured in HU units) to material composition [117, 
118]. 
4.3.2 Facility-specific simulation 
In this work, a method is described to determine the physical properties of the 
proton delivery system, which is based on a set of easily-available reference 
measurements used during the commissioning of the treatment planning system. The 
benefit of this method is that 1) these are standard measurements taken at proton therapy 
centers, and 2) this method does not require simulating the entire treatment head, so it 
does not require blueprints or more extensive measurement data, and 3) requires to be set 
up only one time for each nozzle, allowing the reconstruction of patient-specific 
treatments based on typically-available DICOM data from the treatment plans (images, 
organ structure contours, and the ion beam plan).  
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To demonstrate the entire method from start to finish, computational phantoms 
were used to simulate realistic proton therapy treatments and calculate the incidence 
cancer risk. To do so, two medulloblastoma-type treatments were simulated based on 
facility-specific reference measurement data from the Maryland Proton Treatment 
Center (MPTC). Out-of-field dose was, as expected, shown to be dominated by neutron 
dose, which was still very low. The organ dose calculations were then used to calculate 
risk from these treatments. As expected, from a brain treatment and the low scatter dose 
from neutrons produced within the patient, the resulting risks seem to be low. However, 
if gamma and neutron measurements are available, it would also be recommended to 
compare these simulations with treatment facility-specific gamma and neutron 
measurements, as there may be additional unexpected external dose that needs to be 
considered.  
The currently implied weakness of the Monte Carlo methods is thus its speed, 
being in general significantly slower than using treatment planning system dose or 
measurement. Additionally, a considerable amount of time is required to set up accurate 
proton treatment simulations. However, significant acceleration of dose calculations 
using Monte Carlo is possible utilizing the NIH Biowulf cluster. Currently, TOPAS has 
only multithreading capabilities, however, in the future, multiprocessing capabilities will 
also be available, and this will further speed up simulations. At the moment, this 
deficiency can be overcome by creating scripts that split the simulations to be run 
separately and simultaneously on the NIH Biowulf cluster. Because each delivered spot 
simulation is independent of one another, and the treatments do not have a time-
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dependency, the simulations can simply be split into as many separate simulations as 
there are spots, spot energies, etc. While this will utilize more time on the cluster system, 
it will be possible to run simulations on the scale of hours instead of days.  
 
4.3.3 Risk calculations 
Minimizing the risk from radiotherapy is important for all patients and this is 
especially the case for young patients. In comparison to older cancer patients, pediatric 
patients have organs and tissue which are still actively developing. In addition, pediatric 
patients, ideally, have longer post-treatment lives [63]. Unfortunately, this also means 
that they have a longer time to develop any secondary effects and a small amount of 
radiation deposited in a healthy organ or tissue may increase the probability of such an 
occurrence. Therefore, minimizing the risk of such an occurrence by minimizing the 
dose delivered to normal tissue needs to be a priority.  
In this work, ERR, EAR, and LAR were calculated on two pediatric patient cases 
recreating the most common pediatric CNS tumor. The risk analysis used risk models 
recommended by the BEIR VII committee, after communications with NCI 
epidemiologists to assess the most appropriate method to calculate risk from neutrons 
due to proton therapy. These models will next be expanded to include the NCI risk 
models not based on BEIR VII.  
Risks could not be estimated for all organs because the unexposed baseline 
cancer incidence rates for those organs were not measured and data is not available for 
all organs. In addition, no dose rate factor corrections were used. The BEIR VII risk 
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models are mostly based on Hiroshima and Nagasaki Life Span Study, a cohort that 
received an instantaneous dose. For this work, the radiation dose received could also be 
described as “instantaneous”, so further corrections were not done. 
While the BEIR VII risk models are currently the most appropriate to use when 
considering long-term effects, it should be noted that there are several limitations to 
using these models. To establish the parameters for this model, epidemiologic studies 
were pooled. However, epidemiological studies are not controlled experiments and thus 
are subject to bias from unmeasured factors. In addition, the analysis of risk based on 
organ-specific doses, organ doses received by primary dose were ignored, as these 
models are not accurate at these dose levels and overestimate the risks [10].  
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5 CONCLUSION AND FUTURE WORK 
5.1 OVERVIEW 
In this work, dosimetry methods were established and investigated for use in 
future epidemiologic studies, and risk models were applied to assess risk of second 
neoplasms due to active scanning proton therapy treatments. First, methods were used to 
extend the anatomy available from patient images for studies that require Monte Carlo 
simulations of out-of-field organ doses. Second, TOPAS Monte Carlo simulation of 
scatter was benchmarked using the well-validated code, MCNP. Facility-specific 
measurements were used to create patient-specific treatment dose reconstruction. 
Modules were also created to pre-process patient DICOM data which was then coupled 
with facility-specific modules, and input parameters were created. Lastly, post-
processing modules combined the voxel-based dose into organ-based doses, and BEIR 
VII risk models were applied to the two pediatric phantom cases simulated. 
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5.2 ANATOMY EXTENSION 
The author developed a novel method to extend radiological patient images by 
combining them with available computational phantoms, which was called the 
Anatomical Predictive Extension (APE) method. It was confirmed that the APE method 
results in improved dosimetric accuracy for external radiotherapy applications compared 
to dose calculations based on a reference computational phantom. The APE method will 
be useful for researchers to more accurately estimate organ doses outside the treatment 
fields when only partial-body radiological images are available. Finally, as noted before, 
the discrepancy in anatomy in the border region between phantom and patient anatomies 
exists in the merged APE phantom. This requires further investigations, for example 
possible solutions to reduce the discontinuity may involve “smoothing” of defined 
phantom tissue regions using a process analogous to smoothing of images. This would 
also require further investigation into how this affects the estimated dose in the out-of-
field region. 
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5.3 BENCHMARKING TOPAS 
TOPAS is a relatively new Monte Carlo code, with the establishing publication 
published by Perl, et al. in 2012 [70]. The code is based on the well-established 
GEANT4 code, however, the code itself has not been well-established in the areas of 
neutron scatter and scoring. Simulations were created to compare with measurement and 
a more well-established code, MCNP. Benchmarking the neutron fluence with MCNP 
was found to be more appropriate due to detector sensitivity issues for these 
measurements. 
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5.4 PROTON MODELING 
To model facility-specific proton therapy treatments, methods to reconstruct 
absorbed dose received during radiation therapy is necessary for epidemiologic studies. 
Certain methods were investigated to reconstruct patient-specific organ dose from proton 
therapy treatments based on easily available measurements while keeping the method as 
general as possible to allow the code to be extended for future dose calculations of 
patient-specific treatment dose from multiple facilities.  
First, simulations and measurements were matched, and in-house modules were 
created in Python to describe a specific beam delivery system. This allows for the 
conversion of treatment plans to TOPAS input parameter files by computing the optical 
and energy properties of every single pencil beam at the nozzle exits, as a function of the 
nominal beam energy. Then, facility-specific conversion curves are used to convert 
patient-specific data in the DICOM format using DICOM treatment ion plans to input 
parameters for TOPAS simulations. The methods presented in this study model the beam 
optics and energy spectrum of the system and require to be performed just once for each 
system. The calculated conversion curves established for each facility can then be used 
for all subsequent treatment plan simulations from that facility. 
If simulations are shown to be within commissioning standards, the Monte Carlo 
simulations will be able to be used clinically. In addition, other studies of clinical 
interest will also be possible, such as calculating the need to have the treatment planning 
systems account for linear energy transfer (LET) and relative biological effectiveness 
(RBE) dose corrections [45]. 
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5.5 ORGAN AND RISK CALCULATIONS 
 Organ dose calculations of these proton therapy treatments allowed for the 
assessment of risks of the induction of secondary cancer. It has been shown that young 
patients show significantly higher risks than adults or patients of a large stature. Deep-
seated tumors are associated with elevated risks relative to shallow treatment fields [66]. 
This work showed that, as expected, from active scanning proton therapy, the out-of-
field radiation is low. The main contributor to the organ doses are also as expected from 
neutrons produced within the patient. 
In this study, attributable risks for organs outside of the main radiation field for a 
one-year-old and a five-year-old pediatric phantom receiving active scanning treatments 
for a medulloblastoma-type tumor were calculated based on the BEIR VII risk model 
[10]. First, the excess relative risk (ERR) and excess absolute risk (EAR) of cancer 
induction were calculated in the organs from the time of the treatment up to the age of 
100 years. The ERR and EAR value were weighted as recommended by the BEIR VII 
Committee to calculate the lifetime attributable risk (LAR) for the colon, liver, lung, and 
bladders of both phantoms. 
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5.6 FUTURE WORK 
Though the risk of leukemia is the most common concern of second cancers, in 
this study, the risks were not calculated. To calculate radiation-induced leukemia risks, it 
is necessary to estimate the dose to bone marrow. While developing the methods 
described in this paper, it was not possible to extract this information directly from the 
computation phantoms used in this work and therefore requires further investigation into 
the best methodology of estimating this dose. The computational phantoms used in this 
work were in the DICOM format. However, they are also available in a binary format 
with the spongiosa tissue identified. It will be necessary to create a method to first, 
extract the fluence to the spongiosa layer within the skeletal structures. Then, it is 
necessary multiply the fluence by the dose response function, which is the function of 
phantom age, gender, skeletal site, and energy.  
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